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Preface
The completion of the human genome sequence has driven the transition to 
the era of functional genomics, whose main contents are transcriptomics and 
proteomics. The human genome contains about 20,300 genes. However, the 
human transcriptome contains at least 100,000 transcripts, which is much 
more than the number of human genes due to RNA splicing and other factors 
during the transcription of a gene to RNA. Thus, multiple transcripts are often 
derived from one same gene. Each transcript guides the ribosome to synthesize 
an amino acid sequence of a protein. The synthesized protein in the ribosome 
must be translocated and redistributed to the appropriate locations to form 
a special conformation and interact with surrounding molecules, namely a 
complex, to exert its biological functions. Also, protein is modified by many post-
translational modifications (PTMs) and even unknown factors in the process of 
translocation and redistribution. There are about 400–600 PTMs in the human 
body, which are the main factors for the complexity and diversity of proteins, 
namely, protein species or proteoforms. Thus, multiple proteoforms are often 
derived from one same transcript. About 1,000,000 proteoforms are estimated to 
exist in the human body. Actually, a protein is a set of proteoforms. The different 
proteoforms derived from one gene might have different conformations and 
functions. A proteoform is the final functional performer of a gene. Proteoforms 
are the basic units in a proteome. Each proteoform has its own copy number or 
abundance. Therefore, proteoforms further enrich the concept and content of a 
proteome. Studies on proteoforms will offer much more in-depth insights into 
a proteome, which will directly lead to the discovery of reliable biomarkers for 
accurate understanding of molecular mechanisms, the discovery of effective 
therapeutic targets, and for effective prediction, diagnosis, and prognostic 
assessment.
This book focuses on the concept of proteoforms, technologies to study 
proteoforms, and applications of proteoforms. Chapter 1 addresses the complete 
concept of proteoforms, and compares the methods of “top-down” mass 
spectrometry and two-dimensional gel electrophoresis-liquid chromatography-
liquid chromatography-mass spectrometry (2DE-LC/MS). Chapter 2 examines 
the general concepts of proteoforms and the methodological process for 
identifying them. Chapter 3 describes in detail how to prepare proteoforms of 
therapeutic proteins for top-down mass spectrometry analysis, which opens 
up an area for the application of proteoforms in medical science. Chapter 4 
discusses prolactin proteoform pattern alteration in human pituitary adenomas 
compared to control pituitary tissues, which provides an example of the 
application of proteoforms in clinical study. Chapter 5 covers proteoforms in 
acute leukemia, specifically evaluation of age- and disease-specific proteoform 
patterns.
This book presents new advances in the concept, methodology, and applications 
of proteoforms. However, this book contains only a fraction of the very 
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important proteoform studies in medical sciences, which we hope will stimulate 
and encourage researchers who study proteoforms to come forward with 
scientific merits and clinical practice of proteoforms. We strongly believe that 
proteoform study will bring a brighter future for medical sciences and clinical 
practice.
Xianquan Zhan, MD, PhD.
Professor of Cancer Proteomics and PPPM,
University Creative Research Initiatives Center,








The completion of human genome sequence has driven the research focusing 
from structural genomics to functional genomics. Transcriptomics and proteomics 
are two main contents in the era of functional genomics. Human genome contains 
about 20,300 genes [1]. However, RNA splicing and other factors in the transcrip-
tional process from a gene to RNA result in multiple transcripts that are derived 
from the same single-one gene. Thus, human transcriptome is estimated to contain 
at least 100,000 transcripts, much more than the number of human genes. Each 
transcript guides the ribosome to synthesize an amino acid sequence of a protein. 
The synthesized protein in the ribosome must be translocated and redistributed to 
the appropriate locations to form a special conformation and interact with surround-
ing molecules, namely, a complex, to exert its biological functions. Also, protein 
is modified by many posttranslational modifications (PTMs) and even unknown 
factors in the process of translocation and redistribution. An estimated 400–600 
PTMs in human body are the main factors to cause the complexity and diversity of 
proteins, namely, protein species [2, 3] or proteoforms [4, 5]. Thus, multiple pro-
teoforms are often derived from one same transcript, and it is estimated that human 
proteome contains at least 1,000,000 proteoforms [6]. A proteoform is the basic unit 
in a proteome, and it is defined as its amino acid sequence + PTMs + spatial confor-
mation + localization + cofactors + binding partners + a function (Figure 1), which 
is the final functional performer of a gene [6]. A protein is an umbrella term for all 
proteoforms coded by the same gene. Moreover, the different proteoforms derived 
from one same gene might have different conformation and functions. Each proteo-
form has its own copy number or abundance, which can be quantified between given 
conditions [4]. Studies on proteoforms will offer much more in-depth insights into a 
proteome, which will directly lead to the discovery of reliable biomarkers to under-
stand accurate molecular mechanisms, the discovery of effective therapeutic targets, 
and for effective prediction, diagnosis, and prognostic assessment.
It is a big challenge in the methodology to study the over millions of human 
proteoforms [1, 6]. The common bottom-up mass spectrometry (MS)-based strate-
gies cannot identify proteoforms, which in fact only identify protein-coded genes, a 
protein group. This type of method includes stable isotope-labeled two-dimensional 
liquid chromatography-tandem mass spectrometry (2DLC-MS/MS) and stable 
isotope-free 2DLC-MS/MS, which only identify peptides and PTMs (Figure 2) 
[6]. Top-down MS-based strategies have been developed to identify proteoforms 
[7–9]. This type of method can identify proteoforms, which obtains the proteoform 
message including the amino acid sequence and PTMs. However, the obtained 
message of proteoform is only partial information of the above defined proteoform. 
Also, the protein must be purified prior to MS analysis, with different types of 
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protein isolation techniques such as capillary zone electrophoresis (CZE) and liquid 
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chromatography (LC) [10, 11]. Another drawback is the low ratio of signal to noise 
(S/N) in the MS analysis. All of those factors result in a relative low throughput 
in identification of human proteoforms. Currently the maximum throughput of 
top-down MS is up to 5700 proteoforms corresponding to 860 proteins (Figure 2) 
[6]. Two-dimensional gel electrophoresis (2DE)-liquid chromatography-MS 
Figure 1. 
The concept and formation model of proteoform. (Reproduced from Zhan et al. [1, 6], copyright permission 
with open access policy.)
Figure 2. 





(2DE-LC/MS) strategy combines the top-down technique (2DE) and bottom-up 
technique (LC/MS), which is currently superhigh-throughput method to identify 
the large-scale proteoforms [1, 6, 12, 13]. With the innovating concept and practice 
of 2DE, 2DE is a real prefractionation method, which can effectively recognize 
isoelectric point (pI) and the relative mass (Mr)—two essential parameter of a 
proteoform; each 2D gel spot contains over 50 to several hundred proteoforms, and 
most of proteoforms are low-abundance. Currently, the largest 2D gel is 30 cm x 
40 cm, which can separate 10,000 2D gel spots; thus at least 500,000 or 1,000,000 
proteoforms can be identified. LC/MS can identify protein sequences and partial 
PTMs (Figure 2) [1, 13]. 2DE-LC/MS has great potential in analysis of large-scale 
proteoforms. 2DE-LC/MS and top-down MS are complementary in the achievement 
of maximum coverage of human proteoforms in a proteome.
Proteoform is the final functional format of a protein coded by a gene, which 
has important scientific merits in the fields of life sciences and medical sciences, 
and it is the research hot spot and international scientific frontiers. In the past 
1–2 years, one has gradually paid more attention to the proteoform study. A total 
of 532 publications can be obtained through searching in the PubMed dataset with 
the keyword “proteoform or proteoforms.” For example, 24 growth hormone (GH) 
proteoforms were identified with 2DE-LC/MS in human pituitary tissues [14], and 
20 and 22 kDa GH proteoforms functioned in different signaling profiles. Six pro-
lactin (PRL) proteoforms were identified with 2DE-LC/MS and 2DE-Western blot 
in human pituitary tissues, and the proportional ratio of six PRL proteoforms were 
significantly different among different subtype nonfunctional pituitary adenoma 
relative to control pituitary tissues [15]. The six PRL proteoforms bind to different 
long or short PRL receptors to exert their functions. A total of 3090 proteoforms 
were identified with liquid chromatography-MS (LC/MS), and 417 proteoforms 
were identified with sheathless CZE-MS, in seminal plasma [10]. A total of 3028 
proteoforms corresponding to 387 proteins from E. coli cells were identified with 
coupling size exclusion chromatography (SEC) to CZE-activated ion electron trans-
fer dissociation (CZE-AI-ETD) [16]. Human sperm protamine proteoforms were 
identified with a combination of top-down and bottom-up MS [17]. The glioblas-
toma [12, 13] and pituitary adenoma [13–15] tissue proteoforms were investigated 
with 2DE-LC-MS/MS. Proteoforms were identified from several cell lines (HepG2, 
glioblastoma, LEH) with 2DE-LC/MS [18]. Also, proteoform dynamics is also 
investigated underlying the senescence associated secretory phenotype [19].
In summary, development of proteoforms or protein species significantly 
enriches the concept of proteome, which is the next-generation research direction 
in the field of proteomics. 2DE-LC/MS and top-down MS are the complementary 
method to study the large-scale proteoforms. In-depth investigating proteoforms 
in a proteome with different pathophysiological conditions will directly cause to 
deeply understand disease molecular mechanisms, discover the reliable and effec-
tive therapeutic targets, and identify effective predictive, diagnostic, and prognos-
tic biomarkers. Further, each proteoform is involved in a molecular network system 
and has multiple PTMs. It is the research hot spot how different PTMs competitively 
or synergistically affect proteoform structure and functions and their involved 
molecular network system [20–24]. Molecular network-based proteoform pattern 
biomarkers will have more important scientific merits.
Proteoforms are involved in the entire life science and medical sciences. This 
book contains only a fraction of the important frontier “proteoforms,” which serve 
as a spur to stimulate and encourage researchers who study proteoforms to come 
forward with its scientific merits to research and clinical practice. This book will 
focus on the concept of proteoform, technologies to study proteoforms, and appli-
cations of proteoforms.
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S/N ratio of signal to noise
2DE two-dimensional gel electrophoresis
2DLC two-dimensional liquid chromatography
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Abstract
The term proteoform is used to denote all the molecular forms in which the pro-
tein product of a single gene can be found. The most frequent processes that lead to 
transcript modification and the biological implications of these changes observed in 
the final protein product will be discussed. Proteoforms arising from genetic varia-
tions, alternatively spliced RNA transcripts and post-translational modifications 
will be commented. This chapter will present an evolution of the techniques used to 
identify the proteoforms and the importance of this identification for understand-
ing of biological processes. This chapter highlights the fundamental concepts in the 
field of top-down mass spectrometry (TDMS), and provides numerous examples 
for the use of knowledge obtained from the identification of proteoforms. The 
identification of mutant proteins is one of the emerging areas of proteogenomics 
and has the potential to recognize novel disease biomarkers and may point to useful 
targets for identification of therapeutic approaches.
Keywords: post-translational modifications, top-down, mass spectrometry, 
proteomic experiments, clinical application of proteoform
1. Introduction
A surprise from the human genome project was the identification of 23,000 
genes, far fewer than the estimated 100,000. Some events create distinct pro-
teins that articulate various biological processes from cell signaling to genetic 
regulation. Thus, a single gene by allelic variations, alternative splicing and other 
pre-translational mechanisms, such as post-translational modifications (PTMs), 
conformational dynamics and functioning, may generate specific molecular 
forms of proteins, named “proteoforms,” with different structures and differ-
ent functions. Proteoforms or protein species as previously defined [1] could be 
identified by proteomics experiments, which include quantification of protein 
abundance, investigation of changes in protein expression, characterization 
of post-translational modifications (PTMs), identification of protein-protein 
interactions, a measure of isoform expression, turnover rate and subcellular 
localization [2]. Frequent modifications that produce proteoforms are presented 
in Figure 1.
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conformational dynamics and functioning, may generate specific molecular 
forms of proteins, named “proteoforms,” with different structures and differ-
ent functions. Proteoforms or protein species as previously defined [1] could be 
identified by proteomics experiments, which include quantification of protein 
abundance, investigation of changes in protein expression, characterization 
of post-translational modifications (PTMs), identification of protein-protein 
interactions, a measure of isoform expression, turnover rate and subcellular 
localization [2]. Frequent modifications that produce proteoforms are presented 
in Figure 1.
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2. Proteomic experiments
The advance of genomics enabled the sequencing of the genes of an organism, 
but this does not inform which proteins may be present or how they are modified in 
specific situations. The proteomics analyses begin with the combination of multi-
dimensional separation included the chromatographic and gel electrophoresis tech-
niques and the ability of mass spectrometry to identify and to precisely quantify the 
proteins. Many different technologies have been and are still being developed to get 
the information contained in proteoforms. The high-precision mass spectrometric 
measurements as the tandem mass spectrometry (MS/MS or MS2 (peptide mass 
fingerprinting)) can provide structural information on molecular ions that can be 
isolated and fragmented [3, 4]. Mass spectrometry-based proteomics can be carried 
out in a bottom-up or top-down approach.
2.1 Bottom-up proteomics
The bottom-up proteomics also termed “shotgun proteomics,” when the bottom-
up analysis is performed on a mixture of proteins, has traditionally been used. In this 
approach, proteins that could be a simple or complex mixture are digested by chemical 
or enzymatic digestion to generate peptides that are analyzed by way of MS2. It is gen-
erally applied to identify and characterize many peptides in a mixture and deduce the 
identity of the protein to exist in the sample [5, 6]. In strategy bottom-up, the peptides 
mixture resulting of the digestion is fractionated and subjected to multidimensional 
liquid chromatography, which consists of prefractionating of peptides first accord-
ing to their net charge using strong cation exchange chromatography and second, 
according to their hydrophobicity by reversed phase liquid chromatography (RP-LC) 
coupled online with a mass spectrometer [7]. The peptides fragmented within the 
mass spectrometer will provide product-ion mass spectra which are compared with 
in silico-generated MS/MS of the same mass encoded in a protein database. Proteins 
present in the sample are then inferred from the identified peptides [8].
Figure 1. 
Types of proteoforms: RNA splicing and mutations.
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This approach brings up several disadvantages: the protein inference process 
can be complicated because proteins often contain homologous sequence regions 
and the peptides cannot be either uniquely assigned to a single protein, the same 
peptide might have originated from multiple protein isoforms and/or from distinct 
functional pools of the same protein [2, 9]. The digestion of proteins can cause loss 
sequence variations or information regarding the original amino acid sequence 
and loss information relationship between the amino acid sequence and the PTMs 
belonging to specific proteoforms; thus, it is not capable of identifying proteoforms 
[6, 10]. Introducing the intact protein into the mass spectrometer eliminates these 
problems, the strategy used by the top-down mass spectrometry.
2.2 Top-down proteomics
Differently, of the bottom-up proteomics, the “top-down” approach involves 
direct separation and MS analysis of intact proteins, without previous proteolytic 
digestion. By this method, proteoforms can be characterized since the relation-
ship between the amino acid sequence and the PTMs is preserved, and thus, such 
characterization provides a proteoform-specific understanding of biological 
phenomena [10]. In top-down proteomic, a specific proteoform of interest can be 
directly isolated and, subsequently, fragmented in the mass spectrometer by MS/
MS strategies to map both amino acid variations to obtain information on protein 
masses [11]. The masses describe the complete amino acid sequence, including all 
post-translational modifications, structures, for successful identification [12, 13].
In this proteomic analysis, proteoforms are identified using precursor mass 
and fragmentation data. A precursor mass spectrum (MS1) of intact proteins 
is recorded; the most intense peaks are selected for fragmentation; and mass 
spectra (MS2) of the resulting fragment ions are acquired. On this account, both 
its intact and fragment ions’ masses are measured, and the precursor masses and 
their isotopic distributions present a complex but detailed set of information. 
Upon fragmentation, terminal fragments represent potential cleavage site(s) or 
truncated proteoforms, while (internal) fragment ions can indicate modifica-
tions and, depending on the achieved sequence coverage, possible location. This 
approach routinely allows for 100% sequence coverage and full characterization 
of proteoforms [6, 13]. Top-down mass spectrometry has become the approach 
handy for the analysis of single proteins or simple mixtures of significant biological 
interest. Complexes proteomic samples require that they are fractionated before to 
introduction to the mass spectrometer. Many separation strategies can be applied 
before mass spectrometer only the last step, usually, the RPC coupled to mass 
spectrometry [6, 14].
Proteomic top-down may be denaturing or native. Denaturing top-down 
proteomics (dTDP), the procedure denaturing provides a powerful technique for 
characterizing individual proteins <30 kDa. In these studies, the proteins are dena-
tured prior to their introduction into the mass spectrometer [15]. In this approach, 
protein interactions and quaternary conformations are disturbed by means of 
substance such as organic solvents, reducing agents, strong detergents, non-phys-
iological pH, and/or physical method as heat and pressure [16]. TDP is the most 
disseminated and the scoring system used for identification and characterization of 
proteoforms. It has naturally been developed and tested using datasets derived from 
denatured top-down mass spectrometry experiments [17].
Native top-down proteomics (nTDP) has been used to characterize intact, 
non-covalently bound protein complexes biologically relevant as non-covalent 
protein-protein and protein-ligand interactions, providing stoichiometry and 
structural information since tertiary and quaternary structures of proteins are 
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maintained [6, 18]. The technique utilizes non-denaturing and non-reducing-
buffer conditions during the electrospray ionization process which helps preserve 
the primary and quaternary compositions of proteins and their complexes for MS 
[19, 20]. In native proteoform approach, analytical platforms for high-resolution 
and liquid-phase separation of protein complexes are required prior to native mass 
spectrometry (MS) and MS/MS [21]. During, Escherichia coli proteome analysis, 
144 proteins, 672 proteoforms, and 23 protein complexes were identified, cou-
pling the size-exclusion chromatography and capillary zone electrophoresis-MS/
MS [21]. Other separation techniques have been combined; coupled off-line ion-
exchange chromatography or gel-eluted liquid fraction entrapment electrophoresis 
(GELFrEE), which demonstrates the compatibility of native GELFrEE with native 
and tandem mass spectrometry [21, 22]. An illustrative scheme of the elucidation of 
the proteoform structures by the bottom-up and top-down techniques is presented 
in Figure 2.
3. Separation techniques applied to proteoforms
The number of proteoform species in a proteome could be vast. Separating pro-
teoforms is essential because many high-resolution mass spectrometers due to limited 
charge capacity have a finite ability to detect proteoforms. High-resolution separation 
techniques for complex protein samples are significant challenges of top-down pro-
teomics. To optimize proteome coverage, separation, and multidimensional combina-
tions, strategies are employed, thus, to reduce the complexity of the samples [23]. The 
strategies of separation of proteoforms are based on your intrinsic characteristics and 
physicochemical properties, such as mass/size, isoelectric point and hydrophobic-
ity. Advances in instrumentation, chromatographic and electrophoretic separation 
Figure 2. 
Comparative scheme between top-down and bottom-up proteomics, showing the best indication of top-down 
use for the identification of proteoforms in complex protein mixtures.
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strategies have been developed to separate intact proteins [20] since polyacrylamide 
two-dimensional gel electrophoresis (2D-PAGE) [24, 25] to the development of gel-
eluted liquid fraction entrapment electrophoresis (GELFrEE), capillary zone electro-
phoresis (CZE) [20, 24–26]. Specific columns are also developed for classical methods 
of separation such as hydrophobic interaction chromatography (HIC), hydrophilic 
interaction chromatography (HILIC), reversed phase liquid chromatography 
(RPLC), chromatographic ion exchange (IEX) and size exclusion (SEC) [21–23, 27]. 
Some separations can be on-line with a mass spectrometer as separations chromatog-
raphy and capillary electrophoresis, but many others can be applied off-line only [26]. 
Off-line separations approach, independent of the mass spectrometer, is flexible and 
diversified, allowing the use of diverse techniques of separations, although it is more 
laborious considering the time of collection and treatment of the fractions. Off-line 
separations system consists of three steps: separation of the sample compounds in the 
first dimension; a collection of different fractions for subsequent sample treatment; 
and injection of each of the fractions in the second dimension to be subject to analysis 
[20]. On-line separations, coupled directly to mass spectrometry, allow increased 
throughput and substantially reduce sample handling, but have limitations to sample 
loading, data acquisition and separation conditions [6, 26]. Many techniques of 
fractionation and separation can be combined to reduce the complexity of samples, 
and an off-line approach coupled with an on-line separation may be necessary since 
most proteomic samples have such complexity that they need multiple separation 
steps combined in multidimensional separations [27].
3.1 Sample preparation for top-down proteomics
The preparation of samples is one of the most critical steps for top-down 
proteomics. Conventional buffers for protein extracting as the detergents sodium 
dodecyl sulfate (SDS) and Triton X-100 are not compatible with MS [12]. Many 
methods for lysing samples use saline buffers, reducing agents, and protease and 
phosphatase inhibitors to extract proteoform avoiding alteration or degradation. 
Post extraction is needed to remove or replace nonvolatile salts that suppress MS 
signal by forming adducts to protein ions and increase the chemical noise [26]. The 
most strategies of proteins solubility for proteoforms studies, despite preserving 
many covalent interactions, denature proteins prior to MS and destroy important 
interactions such as protein-protein. In general, these interactions are essential for 
many different cellular processes [28]. In procedures for top-down native, the pH 
must be kept neutral and isolating, and fractionating of proteoforms complexes 
cannot contain denaturing agents such as strong detergents, reducing agents and 
organic solvents [29]. For these proteins to remain in their native states, a buffer is 
generally used for maintaining physiological ionic strength and neutral pH of the 
sample. To minimize noise associated with common buffer and others numerous 
interfering components, top-down sample cleanup methods should be applied; 
for example, protein precipitation and molecular weight cut-off ultrafiltration. 
Donnelly’s et al. guide is one of the best-practice protocols for MS of intact proteins 
from mixtures of varying complexity [30].
3.2 Two-dimensional gel electrophoresis (2DGE)
2D-PAGE is an electrophoretic separation technique still used to separate intact 
proteins; the protein separation in 2D-PAGE is based on the isoelectric point and 
molecular weight (MW) of the proteins. This technique was introduced by O’Farrell 
[31], and it separates cellular proteins under denaturing conditions and enables the 
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maintained [6, 18]. The technique utilizes non-denaturing and non-reducing-
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Figure 2. 
Comparative scheme between top-down and bottom-up proteomics, showing the best indication of top-down 
use for the identification of proteoforms in complex protein mixtures.
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generally used for maintaining physiological ionic strength and neutral pH of the 
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interfering components, top-down sample cleanup methods should be applied; 
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molecular weight (MW) of the proteins. This technique was introduced by O’Farrell 
[31], and it separates cellular proteins under denaturing conditions and enables the 
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resolution of hundreds of proteins. In the first dimension, the separation is based 
on the proteoforms net electric charge (isoelectric point) of each protein and in the 
second dimension, in the presence of sodium dodecyl sulfate (SDS), proteins will 
be separated according to their molecular mass [31, 32]. The denaturing conditions 
introduced to O’Farrell [31] for first dimension comprise conducting a sample 
preparation, using high concentration molar of urea (9 mol/L), nonionic detergent 
(Nonidet NP-40) and a thiol reagent (2-mercaptoethanol), obtaining in this way an 
efficient separation of the proteins contained in the complex sample [33]. The use, 
in the first dimension, of tube gels and ampholytes to establish the pH gradient was 
replaced by the introduction of immobilized pH gradients (IPG strips). A significant 
advance on 2D-PAGE occurred with the development of the IPGs by [34] available 
in various ranges of pH and size. The IPG in polyacrylamide gels allows an efficient 
and reproducible separation of the proteins. In IPGs, the carrier ampholytes are 
attached to acrylamide molecules and cast into the gels to form a fixed pH gradient 
and covalently bound to a film backing. In this case, the buffering groups are grafted 
to the acrylamide gel matrix, the gradients cannot drift, and the gel slabs can be cut 
to narrow, usually 3 mm wide. Using IPG strips, the first-dimension separations 
are more reproducible and have high throughput and high resolution. The IPGs are 
much easier to handle, and there is the convenience provided by commercial produc-
tion of IPG strips made [33, 35, 36].
3.3 Differential in gel electrophoresis (DIGE)
Conventional 2D gels were revolutionized with the introduction of the differen-
tial gel electrophoresis (DIGE), which allow the accurate and reproducible quan-
tification of multiple samples by the relative intensity of fluorescent-dyed protein 
spots that are quantified within the same gel. Difference gel electrophoresis enables 
the accurate quantification of changes in the proteome, including proteoforms 
[37]. It is a strategy that has been developed for the quantitative analysis of intact 
proteins, and provides important information about changes caused by events such 
as truncation, degradation, genetic code variation, alternative splicing, post-trans-
lational processing and PTMs [37, 38]. The proteins in each sample are covalently 
tagged with different color fluorescent dyes, known as CyDye DIGE fluorescent. 
Fluorescent labeling of proteins is performed prior to 2D-DIGE, and then minimal 
labeling is often performed, such that <5% of proteins are labeled, thus reducing 
interference with downstream mass spectrometric analysis [39]. 2D DIGE involves 
the use of a reference sample, known as an internal standard, which comprises equal 
amounts of all biological samples in the experiment [39]. The major advantages of 
DIGE are the high sensitivity and linearity of the dyes utilized, its straightforward 
protocol, as well as its significant reduction of inter-gel variability, which increase 
the possibility to unambiguously identify biological variability and reduce bias from 
experimental variation [39, 40].
3.4 Gel-eluted liquid fraction entrapment electrophoresis (GELFrEE)
GELFrEE is a type of approach based on protein array developed to overcome 
the difficulties related to gel-based. It is one robust strategy that promotes size-
based separation of proteoforms (applied to proteins 10–250 kDa) in the liquid 
phase with high resolution. GELFrEE is a electrophoresis to accommodate broad 
mass range separation of proteins, and the separation can be performed under 
denaturing or also been adapted for native-state size separations, where the tertiary 
and quaternary structures of the proteins are maintained [16, 22, 41]. In GELFrEE, 
the gel column is used to achieve electrophoretic separation of proteins, analogous 
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to SDS-PAGE. The proteins are loaded onto the top of a tube containing poly-
acrylamide gel; for separation to occur, a voltage is applied between the anode and 
cathode reservoirs which are then eluted into the liquid-phase for manual collec-
tion, securing that higher molecular weight proteins are not continually diluted and 
dispersed across many fractions [6]. The detergents incompatible with MS can be 
removed using organic solvent precipitation before online LC-MS. Spin columns 
are coupled in-line matrix removal platform to enable the direct analysis of samples 
containing SDS and salts detergents used in native mode [6, 42, 43]. This technique 
has the advantage of separating proteoforms over a wide mass range in short time 
and at high load, but there is the disadvantage of loss of resolution in the detergent 
removal stage; an acid labile surfactant may be an alternative to SDS [44]. Many 
combinations on-line or off-line GELFrEE with other fractionation techniques 
have been applied for optimal workflows for large-scale intact protein analysis. The 
fractions obtained from the electrophoretic step GELFrEE (for molecular-weight-
based fractionation) are submitted to a second separation dimension. Li et al. [18] 
identified 30 proteins in the mass range of 30–80 kDa from Pseudomonas aerugi-
nosa, fractionated by GELFrEE, analyzed by CZE-ESI-MS platform. However, the 
workflow of additional separation procedure most commonly performed is using a 
GELFrEE-LC-MS/MS [45–47].
3.5 Capillary zone electrophoresis
CZE has been the most common CE mode applied to the mass spectrometry of 
intact proteins. It is a method of proteoforms separation based on electrophoretic 
mobility differences that do not require a stationary phase [20, 48]. This approach 
provides fast and efficient separations. The sample is injected into an electroosmotic 
flow generated by the potential difference between two ends of a capillary filled 
with an aqueous solution, and the molecules are separated by the electrophoretic 
mobility difference. Capillary zone electrophoresis (CZE) offers alternative and 
high-capacity separation of proteoforms based on their sizes and charges, and are 
useful for the separation of high-mass proteoforms by not having stationary phase 
[49, 50]. CZE has been an alternative to RPLC; for example, CZE-MS interfaces 
have better sensitivity to detection, and it can produce more protein identifications 
from complex proteome samples than typical RPLC-MS [51]. The combination of 
methods CZE has led to efficient separation and highly sensitive detection of intact 
proteoforms with the benefit of low sample amount needed, inclusive for native 
proteomics, but some challenges still need to be overcome [20, 52].
3.6 Liquid chromatography systems
Liquid chromatography is the main proteomic approach used for protein 
separation in the mono- or multidimensional modes, which is ideally suited for 
proteomics because it can be interfaced with MS. The basic principle of chro-
matographic separation is the different affinity of analytes for the stationary and 
mobile phase. The LC-based separation methods have the advantage that they can 
be coupled directly with MS [53, 54]. Various orthogonal separation techniques 
using different stationary phase with different types interactions selectivity, two-
dimensional LC separation (2D LC), and multidimensional LC separation (MDLC) 
are often combined to improve intact protein separation and proteoform coverage 
and to increase the dynamic range of detection. Multiple orthogonal separations 
include reversed phase (RP), ion exchange (IEX), size-exclusion (SEC), hydrophilic 
interaction liquid chromatography (HILIC) and hydrophobic interaction liquid 
chromatography (HIC).
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from complex proteome samples than typical RPLC-MS [51]. The combination of 
methods CZE has led to efficient separation and highly sensitive detection of intact 
proteoforms with the benefit of low sample amount needed, inclusive for native 
proteomics, but some challenges still need to be overcome [20, 52].
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Liquid chromatography is the main proteomic approach used for protein 
separation in the mono- or multidimensional modes, which is ideally suited for 
proteomics because it can be interfaced with MS. The basic principle of chro-
matographic separation is the different affinity of analytes for the stationary and 
mobile phase. The LC-based separation methods have the advantage that they can 
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interaction liquid chromatography (HILIC) and hydrophobic interaction liquid 
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3.6.1 Reversed phase liquid chromatography separation (RPLC)
The separation of the proteoforms in RPLC is based on their hydrophobic-
ity using a non-polar stationary phase and a polar mobile phase; the analytes are 
subsequently eluted using increasing concentrations of organic solvents. The 
RPLC approach is widely used for complex intact protein sample separation and 
fractionation, and when coupled online with MS, it is the most prevalent approach 
for studying complex intact protein samples in top-down proteomics [13, 55]. 
Efficient separations to improve peak capacity have been achieved with the use of 
longer columns’ smaller particle sizes in ultra-high pressure LC systems such as 
long column ultrahigh-pressure liquid chromatography (UPLC). Particle gener-
ally, either silica-bonded or polymeric-bonded octadecyl (C18), octyl (C8), or 
other shorter alkyl chains stationary phases are used such as C4 and C5 for intact 
protein separation [56–58]. The separation of the proteoforms in RPLC is based on 
their hydrophobicity using a non-polar stationary phase and a polar mobile phase; 
the analytes are subsequently eluted using increasing concentrations of organic 
solvents. Effective separations to improve peak capacity have been achieved with 
the use of longer columns smaller particle sizes in ultra-high pressure LC systems 
such as long column ultrahigh-pressure liquid chromatography (UPLC). Particle 
generally, either silica-bonded or polymeric-bonded octadecyl (C18), octyl (C8), 
or other shorter alkyl chains stationary phases are used such as C4 and C5 for intact 
protein separation [55–57]. Due to extreme complexities, limited sample loading 
amounts, and large dynamic ranges of intact protein samples, RPLC alone may 
not provide sufficient proteome coverage for top-down proteomics. One common 
way to increase peak capacity in RPLC and increase the proteome coverage is to 
include 2D RPLC or multiple orthogonal separation steps during analysis. Some 
high- resolution techniques combined with RPLC, for separation of proteins and 
proteoforms, for example, IEX-HILC-RPC/MS, high-pH and low-pH RPLC 2D  
(2D pH-RPLC-RPLC), are used for mass spectrometry compatible [58, 59].
3.6.2 Ion exchange chromatography (IEX)
Ion-exchange chromatography is a LC technique for proteins separation for 
top-down proteomics based on differences in charge of the analyte. IEX can be 
applied in cation- and anion-exchange modes. Increasing the ionic strength of 
the mobile phase is used to elute analytes from the charged stationary phase. 
The efficiency in the separation of proteins in IEX is related to conditions to salt 
concentrations and pH elution process applications that can be well versatile. 
This approach is often employed to carry out the first dimension followed by RP 
chromatography in the second dimension to 2DLC, or 3DLC strategy using, for 
example, IEX-HILIC-RPC/MS.
3.6.3 Size-exclusion chromatography (SEC)
Size-exclusion chromatography is part of the intact protein analysis workflow. 
The fractionation occurs in the difference in the accessibility of proteins to the 
intraparticle pore volume of the resin, in the non-adsorptive mode of solute inter-
actions with the stationary-phase surface. The proteins migrate through a porous 
polymeric column and are separated by their hydrodynamic volume, with more 
abundant proteins eluting before smaller ones due to their lower accessibility to 
the interior of the packing materials. The selectivity is provided by the column, 
defined by the size of the intraparticle pore diameter; thus, the efficiency in the 
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SEC separation is mainly governed by the particle diameter [60, 61]. SEC has the 
advantage that can be realized in several types of solutions; however, it is not a high-
resolution separation method, in addition to promoting the dilution of the sample. 
To increase the performance of SEC, different aspects with respect to column 
technology and instrumentation have been addressed. Huang et al. [62] developed 
a simple and efficient method SEC-based separation of proteins using RP columns 
(RP-based SEC performed). They have applied high concentrations of acetonitrile 
with trifluoroacetic acid as an acid modifier which prevented interactions between 
proteins and the stationary phase and allowed the RP column to act as an SEC 
column to separate proteins based on their molecular weight. This innovation 
showed that the RP-based SEC performed better than conventional SEC. Cai et al. 
[63] innovated the SEC-based separation. They developed a serial size exclusion 
chromatography (sSEC) strategy to enable high-resolution size-based fractionation 
of intact proteins. They combined SEC with different pore sizes in series and an 
increase in sufficient separation length, providing an extension of fractionation 
range and higher-resolution separation of proteins pool. This strategy of sSEC 
coupled to RPLC quadrupole-time-of-flight mass spectrometry provided improved 
proteome coverage [63].
3.6.4 Hydrophobic interaction chromatography (HIC)
HIC is a technique that separates proteins based on hydrophobicity with high 
resolution for the separation of intact proteins, main native conditions, and is 
an alternative MS-compatible LC if appropriate salt is used in the mobile phase 
[14, 59]. In this approach, protein’s tertiary structure binds to a hydrophobic surface 
material in the presence of salt and then elutes in order of increasing surface hydro-
phobicity. The stationary phases used for HIC generally feature low density and 
moderate hydrophobic ligands, and resins that are less hydrophobic as compared to 
their counterparts used in RPLC, being the most.
3.6.5 Hydrophilic interaction chromatography (HILIC)
Hydrophilic interaction chromatography is a technique successfully applied 
to the separation of proteins and proteoforms. HILIC has the ability to retain and 
resolve highly polar compounds, based on a complex retention mechanism, involv-
ing hydrophilic partitioning and polar interactions; in other words, the analytes 
are eluted based on their hydrophilicity [64, 65]. In HILIC, the stationary phase is 
polar and often consists of a silica support that can be unmodified or modified with 
a polar surface chemistry, such as zwitterionic sulfoalkylbetaine, amide, diol, and 
aminopropyl; and the mobile phase consists of water and 60–95% of an aprotic, 
miscible organic solvent, usually acetonitrile (ACN) or acetone, with at least 3% 
of water. An organic solvent is used in loading HILIC columns to drive hydrophilic 
portions of proteins to interact with a hydrophilic stationary phase. Elution using a 
gradient from an organic solvent to an aqueous buffer allows desorption and elution 
of proteins from the column [66–68]. HILIC is MS-compatible LC technique for 
protein analysis. Therefore, coupling HILIC techniques in online or off-line two-
dimensional LC workflows has increased the efficiency on the LC-MS analysis of 
complex protein samples, HILIC to be complementary and orthogonal to RPLC 
[65, 69]. Gargano et al. [70] implemented a capillary HILIC-MS method that can be 
used as a high-resolution approach to separate complex mixtures of proteins using 
wide mobile-phase gradients. Salt-free pH-gradient IEX-HILIC was used as the 
second dimension for separating differentially acetylated/methylated intact protein 
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SEC separation is mainly governed by the particle diameter [60, 61]. SEC has the 
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a polar surface chemistry, such as zwitterionic sulfoalkylbetaine, amide, diol, and 
aminopropyl; and the mobile phase consists of water and 60–95% of an aprotic, 
miscible organic solvent, usually acetonitrile (ACN) or acetone, with at least 3% 
of water. An organic solvent is used in loading HILIC columns to drive hydrophilic 
portions of proteins to interact with a hydrophilic stationary phase. Elution using a 
gradient from an organic solvent to an aqueous buffer allows desorption and elution 
of proteins from the column [66–68]. HILIC is MS-compatible LC technique for 
protein analysis. Therefore, coupling HILIC techniques in online or off-line two-
dimensional LC workflows has increased the efficiency on the LC-MS analysis of 
complex protein samples, HILIC to be complementary and orthogonal to RPLC 
[65, 69]. Gargano et al. [70] implemented a capillary HILIC-MS method that can be 
used as a high-resolution approach to separate complex mixtures of proteins using 
wide mobile-phase gradients. Salt-free pH-gradient IEX-HILIC was used as the 
second dimension for separating differentially acetylated/methylated intact protein 
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isoforms in histone family and combined this separation with RPLC online in the 
first dimension to better separation and characterization of intact histones [71].
4. Mass spectrometry
Proteomic experiments, MS based on comprehensive and total characteriza-
tion of proteoform from a biological system, besides efficient separation, employ a 
combination of sensitive detection and accuracy of intact proteins. The technology 
for identification by MS to top-down proteomics has gained impulse. The accuracy 
of mass spectrometric characterization of polypeptides involves improvement on 
ionization, fragmentation and detection conditions. Tandem MS can confirm the 
protein identification based on the daughter ions and characteristics of the obtained 
peptide map and primary structure, which thereafter provide exact localization of 
post-translational or other modification sites. Data-independent acquisition (DIA) 
methods have been alternatively used to analyze proteoforms particularly suited 
to the study of PTMs [72]. DIA focuses on the identification and quantitation of 
fragment ions that are generated from multiple peptides contained in the same 
selection window of several to tens of m/z, that is, the fragmentation spectra of all 
the peptides are acquired in each cycle time without any preselection of the precur-
sor ions [73].
The mass spectrometers are compounded basically into a sample inlet, an ion 
source, a mass analyzer and a detector [74, 75]. Although MS appeared more than a 
century ago, its application to protein analysis began in the 1990s, because existing 
ion sources only allowed the ionization and analysis of inorganic molecules and 
small organic molecules and proteins are not easily transferred to the gas phase 
and ionized by the size [76, 77]. Advancement of mass spectrometry technology 
occurred with the new instrumentation ionizer, matrix-assisted laser desorption/
ionization (MALDI) and electrospray ionization (ESI) [78–80]. The development 
of the mass analyzer applied to analyze intact proteins contributed to the mass 
spectrometry identification of the proteoforms. Mass analyzers with a high level 
of resolving power and sensitivity as time-of-flight (TOF), Orbitrap, Fourier 
Transform Ion Cyclotron Resonance (FT-ICR), or the combination of multiple mass 
analyzers in series, created a powerful tool for top-down MS characterization of 
proteoforms [78, 81, 82]. Most top-down proteomics (TDP) studies have used some 
form of tandem-MS fragmentation techniques, for intact proteins sequencing with 
greatly resolving power and high mass accuracy as: collisionally activated dissocia-
tion (CAD), collision-induced dissociation (CID), electron transfer dissociation 
(ETD), electron-capture dissociation (ECD), higher-energy collisional dissociation 
(HCD), infrared multiphoton dissociation (IRMPD) and ultraviolet photodissocia-
tion (UVPD). These examples of fragmentation strategies can provide additional 
information on the amino acid sequence and PTMs for identification of proteo-
forms [74, 75, 79, 83]. The mass spectrometer sample introduction can be through 
the traditional RPLC-MS, by CZE-MS or embedded in a matrix on a target plate 
[74, 84]. Mass spectrometers that use different types of analyzers for the first and 
second stages of mass analysis (hybrid MS instruments) are employed to maximize 
proteoform characterization top-down MS-based. Still, software tools for the 
identification and quantification of proteoforms need to be continuously developed 
to keep up with a demand to quickly and automatically analyze the data generated. 
Many a comprehensive proteoform software tools for proteoform identifica-
tion and construction of proteoform families are freely available: MASH Suite, 
MetaMorpheus, MSPathFinder, Proteoform Suite, TDPortal, TopMG and TopPIC 
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[13, 20] that can be implemented into current top-down workflows consecutive at 
complete and accurate databases.
A common material used is either surface-modified silica or polymeric particles 
coated with short aliphatic groups n-alkyls (propyl, butyl, hexyl, or octyl chains), 
phenyl and others [61, 85]. HIC separation methods have been evaluated and 
optimized as complementary selectivity to RPLC, which offer efficient separation 
for highly orthogonal HIC-RPLC for top-down proteomics [14, 27]. 
5. Clinical applications for proteoform identification
Several studies are carried out aiming to find markers for pathophysiology 
process of Alzheimer’s disease (AD), cancer [86], type 2 diabetes, and chronic 
alcohol abuse, among other diseases. The identification of proteoforms associated 
with different diseases will undoubtedly be an essential dividing mark for early 
diagnosis, prevention and treatment. Some examples for proteoform identification 
applications as apolipoproteins proteoforms, B-type natriuretic peptide (BNP), 
disorders of glycosylation, detection of structural changes in transthyretin, hemo-
globin proteoforms, cystatin C-truncated proteoforms, C-reactive protein, vitamin 
D-binding protein, transferrin and immunoglobulin G (NISTmAb) were discussed 
[86, 87]. In the last 30 years, since the MALDI and ESI approaches were developed, 
only about a dozen of mass spectrometry protein identification tests have been 
described. Here, we present studies involving Alzheimer’s disease and alterations in 
the levels of apolipoproteins associated with lipid metabolism.
5.1 Alzheimer’s disease
In the diagnosis of Alzheimer’s disease (AD), quantification of total Tau protein 
(T-tau), threonine-phosphorylated Tau181 form (P-Tau181), and the 42 amino 
acid peptide, alpha-amyloid isoform (Aβ) are well established as markers present 
in cerebrospinal fluid (CSF). However, there is a constant need for new diagnostic 
markers to identify the disease at a very early stage [87]. A review about the role of 
proteoforms in the pathophysiology process of Alzheimer’s disease was described 
in [88]. The mass spectrometry performance of three canonical proteins, clusterin, 
secretogranin-2, or chromogranin A, was presented. Variations on the levels of Apo 
A-1, a protein with antioxidant and anti-inflammatory properties, in the serum 
or in CSF, are also indicated as a potential marker for AD diagnosis and progres-
sion. Apo A-1 exhibits [86] and inhibits the aggregation and neurotoxicity of an 
amyloid-β peptide in AD [89]. The possible association between apolipoproteins 
increased Apo A-1 levels that were correlated with decreasing risk of dementia [87], 
raising the possibility of a novel role of Apo A-1 in protection against neurological 
disorders [87, 89].
5.2 Apolipoprotein and lipid metabolism
Possible correlations between apolipoprotein levels (Apo C-III, Apo C-I and 
Apo C-II) with dyslipidemia and cardiovascular disease were presented in [86]. 
Apolipoproteins function as the structural components of lipoprotein particles, 
cofactors for enzymes and ligands for cell-surface receptors. Apolipoproteins 
exhibit proteoforms associated with nucleotide polymorphisms (SNPs) and post-
translational modifications such as glycosylation, oxidation and sequence trunked 
[86]. The human apo Cs are protein constituents of chylomicrons, VLDL and 
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increased Apo A-1 levels that were correlated with decreasing risk of dementia [87], 
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disorders [87, 89].
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HDL. The protein APO C-III has 79 amino acids and can be glycosylated in the 
residue of Threonine 48. Initially, four APO C-III isoforms were identified by mass 
spectrometry and later 12 proteoforms. These proteoforms differ by absence of 
glycosylation (APO C-III Oa), glycosylation (APO C-III Ob), addition of one or two 
sialic acid residues (APO C-III 1, APO C-III 2) or addition of fucose at glycosylation 
sites. There are also truncated proteoforms due to amino acid substitution. Increases 
in APO C-III2 levels are associated with a reduction in TG and LDL levels, and 
perhaps this is a possible mechanism for dyslipidemia processes and reduced risk of 
cardiovascular disease (CVD) [86].
5.3 Cancer disease
The identification of novel biomarkers for early clinical-stage cancer detection, 
targeted molecular therapies, disease monitoring and drug development could 
impact on the future care of cancer patients. A systematic study of cancer samples 
using omics technologies, oncoproteomics, is in progress. He et al. summarize the 
advantages and limitations of the critical technologies used in (onco)proteogenom-
ics [90]. In other studies, Zhan et al. [91]compared MALDI-MS, LC-Q-TOF MS 
and LC-Orbitrap Velos MS for the identification of proteins within one spot. They 
described the importance of the development of stable isotope labeling coupled 
with 2DE-LC/MS in a large-scale study of human proteoforms. This powerful 
technique platform identified in Blue-stained 2DE spots at least 42 and 63 proteins/
spot in an analysis of a human glioblastoma proteome and a human pituitary 
adenoma proteome, respectively. A critical study to detect new proteomic markers 
of medullary thyroid carcinoma, combining MALDI-MSI and nLC-ESI-MS/MS 
were developed by [92]. They identified proteins as moesin, veriscan and lumican 
and intratumoural amyloid components, including calcitonin, apolipoprotein 
E, apolipoprotein IV and vitronectin with a potential role in medullary thyroid 
carcinoma pathogenesis [92].
6. Conclusion
In conclusion, the proteoform identification using a proteomic approach can 
be an advance in diagnostic routines and development of precision/personalized 
medicine. Efforts should be concentrated on clinical studies and then on, and one 
aspect that precludes is the cost and complexity of these tests. Therefore, studies to 
simplify sample preparation steps and MS platforms need to be performed to reduce 
cost per test.
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Abstract
A characteristic of many proteoforms, derived from a single gene, is their 
similarity regarding the composition of atoms, making their analysis very chal-
lenging. Many overexpressed recombinant proteins are strongly associated with 
this problem, especially recombinant therapeutic glycoproteins from large-scale 
productions. In contrast to small molecule drugs, which consist of a single defined 
molecule, therapeutic protein preparations are heterogenous mixtures of dozens or 
even hundreds of very similar species. With mass spectrometry, currently high-
quality spectra of intact proteoforms can be obtained only, if the complexity of the 
mixture of individual proteoform-ions, entering the gas phase at the same time is 
low. Thus, prior to mass spectrometric analysis, an effective separation is required 
for getting fractions with a low number of individual proteoforms. This is especially 
true not only for recombinant therapeutic proteins, because of their huge hetero-
geneity, but also relevant for top-down proteomics. Purification of proteoforms is 
the bottleneck in analyzing intact proteoforms with mass spectrometry. This review 
is focusing on the current state of the art, especially of liquid chromatography for 
preparing proteoforms for mass spectrometric top-down analysis. The topic of 
therapeutic proteins has been chosen, because this group of proteins is most chal-
lenging regarding their proteoform analysis.
Keywords: proteoforms, top-down mass spectrometry, therapeutic proteins, 
liquid chromatography, protein purification parameter screening, displacement 
chromatography
1. Introduction
The analysis of proteoforms, often also termed protein species or isoforms, is 
the next level in proteomics. The first comprehensive definition of this subgroup of 
proteins was published by Jungblut et al. [1] and Schlüter et al. [2], using the term 
“protein species”. In 2013, Smith and Kelleher [3] introduced the term “proteoform”, 
which today is widely accepted in the community of proteomics experts. The 
concept of “proteoform” is nearly identical with the concept of “protein species”. 
The only difference is that the proteoform concept is gene-centric and the protein-
species-concept is chemistry-centric.
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For developing methods for comprehensive analysis of proteoforms, the group 
of therapeutic proteins is a suitable training area. Therapeutic proteins are known 
to be rich in the number of proteoforms. Although a therapeutic protein product 
is containing only trace amounts of impurities like host cell proteins, which are 
difficult to detect because of their very low concentration, the analysis of their 
proteoforms is very challenging because of their large number, their similarity and 
their low concentration compared to the main proteoform.
2. Analysis of proteoforms: challenges
The most common method in proteomics is the bottom-up or shotgun approach. 
It relies on the proteolytic cleavage of proteins by proteases like trypsin. The result-
ing peptide mixture is subjected to liquid chromatography coupled to tandem mass 
spectrometry (LC–MS/MS) analysis. Proteins are identified from the LC–MS/MS 
data by comparing the peptide fragment spectra against in-silico fragment spectra 
generated from a protein database [4]. As a rule of thumb, a protein is claimed to 
be identified, if at least two unique peptides are identified representing parts of the 
sequence. Thus, often a sequence coverage of 100% is not obtained. Consequently, 
if this is the case, it can be only stated that a product or several products (proteo-
forms) of a defined gene has been identified. No information about the identity 
of the underlying proteoform is obtained. It can even be assumed that the identi-
fied tryptic peptides may be products of several different proteoforms. For the 
characterization of a therapeutic protein, bottom-up proteomics is a standard 
method. The signals in the LC–MS chromatograms represent tryptic peptides of all 
proteoforms of the therapeutic protein. A defined tryptic peptide, which is present 
in all proteoforms, will form one single monoisotopic signal. Its signal intensity 
represents the sum of this peptide from the different species. The presence of an 
individual proteoform only can be detected, if this proteoform will yield a tryptic 
peptide, a defined phosphor-peptide, which is unique for this proteoform. However, 
it cannot be excluded, that there are several proteoforms containing that peptide. 
As a result, bottom-up proteomics is helpful for getting LC–MS chromatograms 
which can be used as fingerprints of a therapeutic protein, but will give no infor-
mation about the number and composition of proteoforms within the therapeutic 
protein product. The detection of a low abundant proteoform is especially difficult, 
since a unique tryptic peptide of such a proteoform is present in a low amount and 
thereby the signal in a bottom-up proteomics LC–MS chromatogram will have a low 
intensity. Thus, if the detection of different proteoforms is of interest, top-down 
mass spectrometry (TDMS) is the method of choice, because it utilizes the intact 
proteoform for analysis instead of proteolytic peptides.
For performing a TDMS analysis, a purified individual intact proteoform is 
transferred into the MS. From the MS spectrum of the intact ions, the molecular 
weight can be determined. Various techniques are available for fragmentation of 
the intact proteoform such as HCD, CID, ETD, ETHcD, ECD, UVPD and IRMPD, 
yielding different types for fragments, which complement each other [5]. After 
fragmentation, the proteoform can be identified by interpreting the fragment 
spectrum. There are several software tools available for analyzing the TDMS intact 
data [6–8]. The review of Schaffer et al. is recommended as an introduction into 
TDMS [9]. Robust protocols for mass analysis of intact proteins with TDMS were 
recently published by Donnelly et al. [10]. TDMS is requiring sample mixtures of 
low complexity for obtaining high quality spectra of proteoforms. Aebersold et al. 
estimated the number of proteoforms being present in the human organism in the 
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range of approximately a billion [11]. Thus, very efficient purification steps prior to 
the TDMS are required to tackle the huge number of individual proteoforms in cells 
and tissues of body fluids. Beside the excessive number of individual proteoforms, 
their dynamic range is a further challenge.
3.  Analysis of proteoforms of recombinant therapeutic proteins: 
challenges
Similar challenges are associated with recombinant therapeutic proteins. The 
importance of therapeutic proteins has been continually increasing over the past 
years [12, 13]. Currently, several types of therapeutic proteins [14] are available 
in the market including monoclonal antibodies (mAbs), erythropoietin (EPO), 
insulin, human growth hormone and many more. Therapeutic proteins market is 
dominated by the monoclonal antibodies with sales of approximately $123 billion 
in 2017 and will be seen increasing with the upcoming biosimilar market [13]. 
Therapeutic proteins possess several advantages over small molecule drugs due to 
their higher specificity towards drug targets, which are in most cases also proteins 
[15]. This makes therapeutic proteins able to target specific key steps in disease 
pathology [16].
This group of man-made proteins has presumably a significantly higher number 
of proteoforms per gene than proteoforms per gene in vivo, causing a huge number 
of proteoforms within a single recombinant therapeutic protein (rTP) product. The 
heterogeneity is developing during the production of an rTP mainly in the upstream 
processing. The first event increasing the heterogeneity is alternative splicing 
[17–19]. The second critical step is the protein biosynthesis at the ribosomes, in 
which errors can occur. Proteolytic cleavage may happen at any stage after the 
protein has left the ribosome, not only within the host cell, but also extracellularly, 
if host cell proteases have not been removed by purification of the target protein. 
Many therapeutic proteins like conventional monoclonal antibodies or erythropoi-
etin [20] are posttranslationally modified by glycans. Especially, the glycan chains 
are adding an additional factor multiplying the heterogeneity of proteoforms. An 
example of a therapeutic glycoprotein is Etanercept, which is decorated with O- 
and N-glycans. Commercial preparations of Etanercept used as drugs show a very 
high degree of complexity [21]. It can be assumed that therapeutic fusion proteins 
applied to patients like etanercept are containing even hundreds of species, which 
differ in their exact composition of atoms. In addition to glycans, all other forms of 
posttranslational modifications are possible, depending on the nature of the protein 
and the type of the host cells and the upstream parameters.
Why is the heterogeneity of recombinant therapeutic proteins much higher than the 
heterogeneity of gene products in-vivo? Host cells used for the production of recombi-
nant therapeutic proteins are optimized to synthesize a large excess of recombinant 
proteins [22]. However, increasing the expression of proteins does not usually 
correlate to increase in the correctly processed bioactive form of the recombinant 
proteins [22]. Consequently, the probability is increasing, that these overexpressed 
recombinant proteins are underlying errors during synthesis, side reactions of 
enzymes and spontaneous chemical reactions. As a result, the number of recom-
binant species, which have a low quality, is much higher than in a native cell in an 
intact organism [23]. It was reported that overexpressing recombinant therapeutic 
proteins is also accompanied by an increase in high molecular weight aggregates 
and misfolded forms [24]. Thus, it can be assumed that the cellular systems, which 
usually remove low-quality or incorrectly processed proteins, are swamped by 
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these inadequate proteins [25] and thereby these species will not be processed in 
the cell or be eliminated. Beside the enzymatic reactions mainly taking place in the 
upstream-processing, chemical reactions which modify the recombinant therapeu-
tic proteins, can occur during the whole production process including even the final 
product fill and finish or storage [26, 27]. A very common reaction is the oxidation 
of methionine, which can happen on nearly every stage of the production and can 
affect the efficacy of the product.
Is any risk associated with the large number of species? Fortunately, severe side 
effects associated with species, which are not exactly identical with the target 
protein, have been reported very seldomly. An unfortunate case with dramatic 
consequences for a few patients was reported from Seidl et al. [28]. In this case, 
tungsten ions, a contamination which got into the glass vials during the produc-
tion of the vials, induced the dimerization of erythropoietin. As a result, a few 
patients developed autoantibodies against erythropoietin, thereby destroying the 
remaining cells in these patients, which were producing the native hormone. Since 
a therapy with erythropoietin was not possible any more, these patients had to get 
blood transfusions for survival. Non-human glycan structures bound to therapeutic 
proteins, which can occur when producing them in mouse cells, can induce hyper-
sensitivity reactions [29, 30].
More common than severe side effects is the phenomenon that , showing even 
small differences in their composition of atoms compared with the target species, 
make the species less potent than the target species. For example, deamidation, 
causing a + 1 Da shift of the molecular weight, can decrease the efficacy of a 
therapeutic protein [31], as observed with recombinant human interleukin (rhIL)-
15 [32]. Deamidation converts asparagine or glutamine to aspartic acid or glutamic 
acid, respectively. As a result, the polar, uncharged amides are changed into 
negatively charged carboxylic acids, impacting protein surface-charge density and 
surface hydrophobicity, thereby explaining the change of the efficacy of a thera-
peutic protein. Deamidation of asparagine can occur spontaneously at physiological 
pH of 7.4 [32]. A further important modification of proteins is the disulfide bond 
(S-S), which is formed by the oxidation of thiol groups (SH) between two cysteine 
residues resulting in a covalent bond [33], which is decreasing the molecular weight 
of a protein by 2 Da. Disulfide-bonds have an impact on protein stability as well as 
on activities [33]. Du et al. stated that during the manufacturing process, extensive 
reduction of antibodies has been observed after harvest operation or Protein A 
affinity chromatography and multiple process parameters correlate to the extent of 
the reduction [34]. The topic “disulfide bonds of therapeutic proteins” is in depth 
discussed by Lakbub et al. [35].
More details about sources and effects of microheterogeneity are described in 
the excellent reviews of Beyer [36] and Ambrogelly [37].
How large are the differences of the individual proteoforms of a therapeutic protein? 
Proteofroms can vary in all chemical properties known, such as size, isoelectric 
points (pI) [38] and hydrophobicity [39]. The pIs of recombinant erythropoietin 
varies from pH 3.5–6 [38, 40]. Therapeutic proteins are characterized by the 
presence of size variants arising from the manufacturing process or storage condi-
tions when exposed to chemical, physical or conformational stress [41]. These size 
variants may include the N terminus clipped proteins, truncated forms, fragments 
representing sub molecular weight species or improperly assembled therapeutic 
proteins. The formation of dimers or multimers, in which more than two mono-
mers are forming a complex, is a problem, which many therapeutic proteins are 
associated with [42]. Such aggregates can induce adverse immune responses in 
patients [43]. The proteoforms of recombinant erythropoietin are varying within 
a range of 4–6 kDa [20]. Beside these larger differences in size, the composition of 
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atoms of many proteoforms derived from one single gene can be very similar within 
subtypes of proteoforms such as the family of acidic proteoforms. As a result, the 
separation of charge variants by ion exchange usually is successful but the composi-
tion within a single fraction might not only contain one single but also multiple 
proteoforms [44].
4. Separation of proteoforms of therapeutic proteins
4.1  Separation of proteoforms of therapeutic proteins with liquid 
chromatography
Liquid chromatography (LC) is the most common for purification and fraction-
ation of therapeutic proteins [37]. The proteoforms are either separated by size-
exclusion (SEC), making use of different path lengths through chromatographic 
particles related to the size of the proteins, or by adsorption chromatography. The 
latter is applying the principle of separation of molecules by their different veloci-
ties during crossing a column filled with chromatographic particles. The velocities 
are proportional to the affinities of the molecules towards the stationary phase of 
the stationary phase. Depending on the chemistry of the functional groups of the 
stationary phase, different forms of liquid chromatography are possible based on 
adsorption to the stationary phase, highlighted in bold in Table 1.
Table 1 is giving an overview about the different types of separation methods 
and their frequency of application with a focus on therapeutic proteins and in addi-
tion with respect to proteoforms. The numbers of column 2 compared with column 
3 clearly show that the topic of proteoforms is not yet addressed very often. The 
selected reviews will give deeper insights into the different separation methods.
Affinity chromatography using chromatographic material derivatized with 
protein-A is the most common and effective method for the purification of recom-
binant monoclonal antibodies [45]. For the separation of proteoforms of recombi-
nant monoclonal antibodies, it is not very relevant.
Ion exchange chromatography (IEX): charge variants of therapeutic proteins such 
as acidic or basic species can be separated with ion exchange chromatography (IEX) 
[46]. IEX of proteins can be performed with oppositely charged ionic group on 
the stationary phase as either anion exchange or cation exchange chromatography. 
Elution buffers are decreasing electrostatic interactions of the proteins with IEX 
material thereby decreasing the affinity of the protein towards the stationary phase. 
Elution can be either pH or salt based [47]. Salt-based elution is used for IEX with 
ultra violet (UV) online detection. Coupling IEX directly with MS is only possible 
if the elution buffer system is volatile [48]. Acidic species are often related to PTM’s 
like sialic acid or deamidation on asparagine, while basic variants are formed by 
aspartate isomerization, succinimide formation, variants of C terminal lysine and 
N terminal glutamine [49]. IEX is giving relative quantitative information about 
charge variants which can be important for the qualification of manufacturing 
batches [50].
Hydroxyapatite-chromatography (HAP) is based on a material consisting of the 
crystals of calcium hydroxyapatite, described by the formula Ca5(PO4)3(OH). 
HAP can be described as mixed-mode chromatography. The Ca2+ −ions can act via 
electrostatic interactions as anion-exchanger. Also, metal coordination bonds of 
carboxylic groups can be formed with the Ca2+ −ions. With the anionic phosphate 
groups of HAP, positive-charged molecules will be adsorbed by electrostatic 
interactions. Phosphate-, chloride-ion-, and calcium-ion- gradients are common 
as well as multi-component gradients [39]. Therefore, finding appropriate eluents 
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these inadequate proteins [25] and thereby these species will not be processed in 
the cell or be eliminated. Beside the enzymatic reactions mainly taking place in the 
upstream-processing, chemical reactions which modify the recombinant therapeu-
tic proteins, can occur during the whole production process including even the final 
product fill and finish or storage [26, 27]. A very common reaction is the oxidation 
of methionine, which can happen on nearly every stage of the production and can 
affect the efficacy of the product.
Is any risk associated with the large number of species? Fortunately, severe side 
effects associated with species, which are not exactly identical with the target 
protein, have been reported very seldomly. An unfortunate case with dramatic 
consequences for a few patients was reported from Seidl et al. [28]. In this case, 
tungsten ions, a contamination which got into the glass vials during the produc-
tion of the vials, induced the dimerization of erythropoietin. As a result, a few 
patients developed autoantibodies against erythropoietin, thereby destroying the 
remaining cells in these patients, which were producing the native hormone. Since 
a therapy with erythropoietin was not possible any more, these patients had to get 
blood transfusions for survival. Non-human glycan structures bound to therapeutic 
proteins, which can occur when producing them in mouse cells, can induce hyper-
sensitivity reactions [29, 30].
More common than severe side effects is the phenomenon that , showing even 
small differences in their composition of atoms compared with the target species, 
make the species less potent than the target species. For example, deamidation, 
causing a + 1 Da shift of the molecular weight, can decrease the efficacy of a 
therapeutic protein [31], as observed with recombinant human interleukin (rhIL)-
15 [32]. Deamidation converts asparagine or glutamine to aspartic acid or glutamic 
acid, respectively. As a result, the polar, uncharged amides are changed into 
negatively charged carboxylic acids, impacting protein surface-charge density and 
surface hydrophobicity, thereby explaining the change of the efficacy of a thera-
peutic protein. Deamidation of asparagine can occur spontaneously at physiological 
pH of 7.4 [32]. A further important modification of proteins is the disulfide bond 
(S-S), which is formed by the oxidation of thiol groups (SH) between two cysteine 
residues resulting in a covalent bond [33], which is decreasing the molecular weight 
of a protein by 2 Da. Disulfide-bonds have an impact on protein stability as well as 
on activities [33]. Du et al. stated that during the manufacturing process, extensive 
reduction of antibodies has been observed after harvest operation or Protein A 
affinity chromatography and multiple process parameters correlate to the extent of 
the reduction [34]. The topic “disulfide bonds of therapeutic proteins” is in depth 
discussed by Lakbub et al. [35].
More details about sources and effects of microheterogeneity are described in 
the excellent reviews of Beyer [36] and Ambrogelly [37].
How large are the differences of the individual proteoforms of a therapeutic protein? 
Proteofroms can vary in all chemical properties known, such as size, isoelectric 
points (pI) [38] and hydrophobicity [39]. The pIs of recombinant erythropoietin 
varies from pH 3.5–6 [38, 40]. Therapeutic proteins are characterized by the 
presence of size variants arising from the manufacturing process or storage condi-
tions when exposed to chemical, physical or conformational stress [41]. These size 
variants may include the N terminus clipped proteins, truncated forms, fragments 
representing sub molecular weight species or improperly assembled therapeutic 
proteins. The formation of dimers or multimers, in which more than two mono-
mers are forming a complex, is a problem, which many therapeutic proteins are 
associated with [42]. Such aggregates can induce adverse immune responses in 
patients [43]. The proteoforms of recombinant erythropoietin are varying within 
a range of 4–6 kDa [20]. Beside these larger differences in size, the composition of 
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atoms of many proteoforms derived from one single gene can be very similar within 
subtypes of proteoforms such as the family of acidic proteoforms. As a result, the 
separation of charge variants by ion exchange usually is successful but the composi-
tion within a single fraction might not only contain one single but also multiple 
proteoforms [44].
4. Separation of proteoforms of therapeutic proteins
4.1  Separation of proteoforms of therapeutic proteins with liquid 
chromatography
Liquid chromatography (LC) is the most common for purification and fraction-
ation of therapeutic proteins [37]. The proteoforms are either separated by size-
exclusion (SEC), making use of different path lengths through chromatographic 
particles related to the size of the proteins, or by adsorption chromatography. The 
latter is applying the principle of separation of molecules by their different veloci-
ties during crossing a column filled with chromatographic particles. The velocities 
are proportional to the affinities of the molecules towards the stationary phase of 
the stationary phase. Depending on the chemistry of the functional groups of the 
stationary phase, different forms of liquid chromatography are possible based on 
adsorption to the stationary phase, highlighted in bold in Table 1.
Table 1 is giving an overview about the different types of separation methods 
and their frequency of application with a focus on therapeutic proteins and in addi-
tion with respect to proteoforms. The numbers of column 2 compared with column 
3 clearly show that the topic of proteoforms is not yet addressed very often. The 
selected reviews will give deeper insights into the different separation methods.
Affinity chromatography using chromatographic material derivatized with 
protein-A is the most common and effective method for the purification of recom-
binant monoclonal antibodies [45]. For the separation of proteoforms of recombi-
nant monoclonal antibodies, it is not very relevant.
Ion exchange chromatography (IEX): charge variants of therapeutic proteins such 
as acidic or basic species can be separated with ion exchange chromatography (IEX) 
[46]. IEX of proteins can be performed with oppositely charged ionic group on 
the stationary phase as either anion exchange or cation exchange chromatography. 
Elution buffers are decreasing electrostatic interactions of the proteins with IEX 
material thereby decreasing the affinity of the protein towards the stationary phase. 
Elution can be either pH or salt based [47]. Salt-based elution is used for IEX with 
ultra violet (UV) online detection. Coupling IEX directly with MS is only possible 
if the elution buffer system is volatile [48]. Acidic species are often related to PTM’s 
like sialic acid or deamidation on asparagine, while basic variants are formed by 
aspartate isomerization, succinimide formation, variants of C terminal lysine and 
N terminal glutamine [49]. IEX is giving relative quantitative information about 
charge variants which can be important for the qualification of manufacturing 
batches [50].
Hydroxyapatite-chromatography (HAP) is based on a material consisting of the 
crystals of calcium hydroxyapatite, described by the formula Ca5(PO4)3(OH). 
HAP can be described as mixed-mode chromatography. The Ca2+ −ions can act via 
electrostatic interactions as anion-exchanger. Also, metal coordination bonds of 
carboxylic groups can be formed with the Ca2+ −ions. With the anionic phosphate 
groups of HAP, positive-charged molecules will be adsorbed by electrostatic 
interactions. Phosphate-, chloride-ion-, and calcium-ion- gradients are common 
as well as multi-component gradients [39]. Therefore, finding appropriate eluents 
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is more difficult than with anion-exchange chromatography. However, screening 
systematically appropriate parameters of eluent systems should offer the chance to 
separate proteoforms. As indicated in Table 1, HAP is not very often applied for the 
chromatography of therapeutic proteins, which may be associated with the fact that 
it is more complex to find optimal elution systems.
Hydrophilic interaction chromatography (HILIC) is making use of high affinities 
of polar and hydrophilic molecules to hydrophilic stationary phase [51, 52]. Usually 
the sample application buffer has a high content (>80%) of an organic solvent 
like acetonitrile. Thus, it is working well for glycans. However, proteins under 
these conditions may precipitate. If proteoforms will not precipitate, HILIC is an 
Separation method Hits of the PubMed search: 
monoclonal recombinant 
antibody OR therapeutic-
proteins OR biotherapeutics 
AND “name of the separation 
method: left column”







Affinity chromatography (AF) 1046 189 [45, 100]
Anion exchange 
chromatography (AEC)
80 20 [101, 102]
Cation exchange 
chromatography (CEX)









8 3 [51, 52]
Immobilized metal affinity 
chromatography (IMAC)










Liquid chromatography (LC) 1969 308 [109]
Two dimensional liquid 
chromatography (2D-LC)
11 2 [110, 111]
Capillary electrophoresis (CE) 151 31 [112]
Two dimensional 
electrophoresis (2DE)
12 4 [38, 113]
The second column is listing the hits got by screening the knowledgebase PubMed (screening date 24.07.2019 
8:00 pm) with the search terms: “monoclonal recombinant antibody OR therapeutic-proteins OR biotherapeutics 
AND anion-exchange-Chromatography”. The third column is presenting the hits after adding the filter: “AND 
(isoform OR variant OR species OR proteoform)”. In bold: Forms of liquid chromatography based on adsorption.
Table 1. 
Overview about methods for the separation of therapeutic proteins showing the frequency of their application 
and recommended reviews.
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interesting alternative for other forms of adsorption chromatography, especially, if 
precipitation proteoforms will be removed from the proteoforms of interest.
Hydrophobic interaction chromatography (HIC) is yet another method which can 
be used for separating different proteoforms of a therapeutic protein. These separa-
tions rely on the varying hydrophobicity profiles due to change in conformation of 
the protein HIC separations use reverse salt gradients and can operate in nondena-
turing mode [53]. HIC was presented as a reliable method for monitoring oxidation 
of tryptophan residues in complement determining region (CDR) of recombinant 
mAbs [54]. HIC is effective in resolving the proteoforms of antibody drug conju-
gates varying in drug to antibody ratio [55]. Charge variants coeluting with IEX 
can be resolved with HIC in the second dimension of separation. Douglas and 
colleagues demonstrated the separation of carboxy terminal variants, isomerization 
variants with HIC which could not be resolved at the IEX level [56]. Quantitative 
information of the succinimide variants was given by HIC with TSKgel butyl-NPR 
column [57]. Similar application can be also found in detection of impaired disul-
fide bonding. Typical HIC buffers like ammonium sulfate are requiring desalting 
of the proteins prior to the MS [58]. Recently, direct coupling of HIC with MS for 
detailed characterization of mAbs was demonstrated by applying a volatile ammo-
nium acetate buffer [53].
Immobilized metal-affinity-chromatography (IMAC) is widely used for enriching 
recombinant proteins with histidine tags from a protein extract from host cells. For 
production of therapeutic proteins, IMAC is not very often used, because metal 
ions are bleeding into the product. Metal ions like nickel or copper are critical for 
patients. For the separation of subgroups of proteoforms for analytical purposes 
also IMAC is an option.
Mixed mode chromatography (MM) is performed with stationary phases which 
consist of at least two different functional groups [59], like hydroxy apatite (see 
above). Consequently, a MM material offers two or more types of chromatography. 
HAP is combining anion exchange (AEX), cation exchange (CEX) and IMAC. Also, 
with SEC mixed mode chromatography is possible, as described by Schlüter 
et al. [60]. In that study the electrostatic interaction induced by anionic sugars, 
which are part of a dextran polymer, were used to separate vanillylmandelic acid, 
glycine and phenylalanine from each other with a SEC column, which is usually 
applied for the separation of proteins in the range of 10–100 kDa. Mixed mode 
chromatography is not very often described for the chromatography of therapeutic 
proteins (Table 1), but it has a huge potential for the separation of proteoforms. 
For successful separations a rational screening of appropriate parameters is 
recommended.
Size exclusion chromatography (SEC) is a gold standard for monitoring the pres-
ence of aggregates of therapeutic proteins. SEC uses porous stationary phase mate-
rial wherein the size variants are separated based on the differential access to the 
pores of the SEC material resulting in different path lengths in relationship to the 
size [61, 62]. SEC is effectively separating low molecular weight and high molecular 
weight species in mAbs [63]. SEC has found many applications like stability test-
ing [64], quality control during manufacturing [65], in depth characterization of 
antibody-drug-conjugates (ADC’s) [66] and assessing aggregate content in biosimi-
larity studies [67]. However, resolution of SEC is rather poor to clearly distinguish 
individual size variants. Non-specific adsorption to the SEC material can result in 
peak broadening thereby decreasing resolution. This problem may be minimized 
by use of organic modifiers in mobile phase or adjusting the pH in relation to the 
pI of therapeutic protein [61]. Advances in the chemistries of stationary phases 
incorporating very small core-shell particles or the use of sub-micron particles are 
improving the resolution of SEC columns [61].
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is more difficult than with anion-exchange chromatography. However, screening 
systematically appropriate parameters of eluent systems should offer the chance to 
separate proteoforms. As indicated in Table 1, HAP is not very often applied for the 
chromatography of therapeutic proteins, which may be associated with the fact that 
it is more complex to find optimal elution systems.
Hydrophilic interaction chromatography (HILIC) is making use of high affinities 
of polar and hydrophilic molecules to hydrophilic stationary phase [51, 52]. Usually 
the sample application buffer has a high content (>80%) of an organic solvent 
like acetonitrile. Thus, it is working well for glycans. However, proteins under 
these conditions may precipitate. If proteoforms will not precipitate, HILIC is an 
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interesting alternative for other forms of adsorption chromatography, especially, if 
precipitation proteoforms will be removed from the proteoforms of interest.
Hydrophobic interaction chromatography (HIC) is yet another method which can 
be used for separating different proteoforms of a therapeutic protein. These separa-
tions rely on the varying hydrophobicity profiles due to change in conformation of 
the protein HIC separations use reverse salt gradients and can operate in nondena-
turing mode [53]. HIC was presented as a reliable method for monitoring oxidation 
of tryptophan residues in complement determining region (CDR) of recombinant 
mAbs [54]. HIC is effective in resolving the proteoforms of antibody drug conju-
gates varying in drug to antibody ratio [55]. Charge variants coeluting with IEX 
can be resolved with HIC in the second dimension of separation. Douglas and 
colleagues demonstrated the separation of carboxy terminal variants, isomerization 
variants with HIC which could not be resolved at the IEX level [56]. Quantitative 
information of the succinimide variants was given by HIC with TSKgel butyl-NPR 
column [57]. Similar application can be also found in detection of impaired disul-
fide bonding. Typical HIC buffers like ammonium sulfate are requiring desalting 
of the proteins prior to the MS [58]. Recently, direct coupling of HIC with MS for 
detailed characterization of mAbs was demonstrated by applying a volatile ammo-
nium acetate buffer [53].
Immobilized metal-affinity-chromatography (IMAC) is widely used for enriching 
recombinant proteins with histidine tags from a protein extract from host cells. For 
production of therapeutic proteins, IMAC is not very often used, because metal 
ions are bleeding into the product. Metal ions like nickel or copper are critical for 
patients. For the separation of subgroups of proteoforms for analytical purposes 
also IMAC is an option.
Mixed mode chromatography (MM) is performed with stationary phases which 
consist of at least two different functional groups [59], like hydroxy apatite (see 
above). Consequently, a MM material offers two or more types of chromatography. 
HAP is combining anion exchange (AEX), cation exchange (CEX) and IMAC. Also, 
with SEC mixed mode chromatography is possible, as described by Schlüter 
et al. [60]. In that study the electrostatic interaction induced by anionic sugars, 
which are part of a dextran polymer, were used to separate vanillylmandelic acid, 
glycine and phenylalanine from each other with a SEC column, which is usually 
applied for the separation of proteins in the range of 10–100 kDa. Mixed mode 
chromatography is not very often described for the chromatography of therapeutic 
proteins (Table 1), but it has a huge potential for the separation of proteoforms. 
For successful separations a rational screening of appropriate parameters is 
recommended.
Size exclusion chromatography (SEC) is a gold standard for monitoring the pres-
ence of aggregates of therapeutic proteins. SEC uses porous stationary phase mate-
rial wherein the size variants are separated based on the differential access to the 
pores of the SEC material resulting in different path lengths in relationship to the 
size [61, 62]. SEC is effectively separating low molecular weight and high molecular 
weight species in mAbs [63]. SEC has found many applications like stability test-
ing [64], quality control during manufacturing [65], in depth characterization of 
antibody-drug-conjugates (ADC’s) [66] and assessing aggregate content in biosimi-
larity studies [67]. However, resolution of SEC is rather poor to clearly distinguish 
individual size variants. Non-specific adsorption to the SEC material can result in 
peak broadening thereby decreasing resolution. This problem may be minimized 
by use of organic modifiers in mobile phase or adjusting the pH in relation to the 
pI of therapeutic protein [61]. Advances in the chemistries of stationary phases 
incorporating very small core-shell particles or the use of sub-micron particles are 
improving the resolution of SEC columns [61].
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Reversed phase liquid chromatography (RPLC) mainly exploits the differences in 
hydrophobic properties of molecules for their separation. Sample application onto 
RPLC columns is performed with eluents having a high content of water, support-
ing a high affinity of the molecules in the sample towards the stationary phase, 
which is hydrophobic. Elution is achieved with gradients increasing the concentra-
tion of organic solvents in the eluent. Coupling RPLC with the high sensitivity 
detectors can provide qualitative and quantitative information of the cleaved, 
modified proteoforms along with main form [68]. Ambrogelly et al. reported RPLC 
as a method giving a first-hand check of the product quality to help in optimizing 
the purification strategy [69]. When coupled to high resolution mass spectromet-
ric detection, RPLC also allows distinction of the major glycoforms. More than 
a decade ago, Dillion presented RPLC not only for determining the intact mAb 
glycosylation profile but only with the use of high temperature and organic solvents 
with high eluotropic strength coefficients [70]. Many advancement to conventional 
RPLC columns have come up in recent times to improve the separation of large 
therapeutic proteins at milder conditions [71].
The major concern in the use of RPLC for protein separations is the presence 
of organic solvents, which may precipitate proteins. Since precipitation will occur 
on the column, it is very difficult to recognize. In the case of proteoforms, it can 
be assumed that some may be more prone to precipitation than others. As a result, 
the chromatogram, in which signals from some but not all proteoforms are present, 
may be misinterpreted since the chromatogram is giving no information about the 
proteoforms which got lost by precipitation. TDMS protocols often apply RPLC 
for the analysis of proteoforms, because those species, which elute, are present in a 
liquid, which is optimal for electrospray ionization (ESI). Because of the problem 
with precipitation of proteins in RPLC in all TDMS approaches the question is how 
representative the TDMS chromatogram is regarding the original composition of 
proteoforms or vice versa how many proteoforms got lost during RPLC.
Elution modes of liquid chromatography: beside the different types of stationary 
phases, different elution modes are existing, which have an impact on the separation 
of molecules, namely isocratic elution, gradient elution (GE) and displacement elu-
tion (DE). DE is typically using the same sample application buffer and adsorption 
chromatography materials as gradient elution. In contrast to GE, DE is not using a 
salt gradient with an increasing concentration of a salt having a low affinity towards 
the stationary phase, but the elution buffer of DE is consisting of the sample 
application buffer, into which the displacer is added. The displacer ideally should 
have an affinity to the stationary phase higher than any of the sample components. 
After the sample application onto the column is finished, the eluent containing the 
displacer is immediately pumped onto the column. At the beginning, the displacer 
molecules are binding strongly to the top of the column, thereby displacing the 
sample component with the highest affinity. These sample components then dis-
place the sample components with a lower affinity and so on. By this process, bands 
are formed moving down the column, driven by the displacer. The DE is finished, as 
soon as the displacer has saturated the stationary phase of the column completely. 
Within a band a high purity of the component is achieved [72]. DE has been shown 
to be suitable for separation of complex mixture of tryptic peptides [73–75] and 
proteins [76–79]. One of the characteristics of DE is that DE has a different selectiv-
ity compared with GE [77]. This is one important argument for using DE for the 
separation of proteoforms. Thus, it is not surprising, that DE has been applied to the 
separation of proteoforms of therapeutic proteins successfully [46, 80–84].
Rational screening of parameters of liquid chromatography is recommended for 
optimal results of the separation of proteoforms. The first method describing 
multi-parallel high-throughput screening for parameters of liquid chromatography 
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was published 2002 by the group of Cramer [85]. In this case, the authors screened 
for displacers for ion-exchange systems. In the following year the group reported 
a multi-parallel high-throughput screening for displacers based on batch chro-
matography [86]. Thiemann et al. published a similar approach termed protein-
purification parameter screening system (PPS), which was not focusing on the 
identification of appropriate displacers but more general on any kind of parameters 
for adsorption chromatography, independent of the elution mode [87]. The PPS 
was successfully applied for purification and identification of an angiotensin-II 
generating enzyme [88], and for screening for parameters for optimal displace-
ment chromatography of proteins [78, 79]. Rational screening was also used for 
developing a displacement chromatography of proteoforms of a recombinant 
protein with HIC [89].
4.2  Separation of proteoforms of therapeutic proteins with capillary 
electrophoresis
Compared with liquid chromatography, capillary electrophoresis (CE) offers 
better resolving power. CE techniques such as capillary zone electrophoresis (CZE), 
capillary gel electrophoresis (CGE) and capillary isoelectric focusing (CIEF) have 
been adapted for the separation and characterization of proteins [90, 91]. These 
are basic techniques routinely used for quality control [91]. With CGE, the size of 
proteins is characterized, while in CIEF, proteins are separated according to their 
isoelectric point (pI). CIEF is using pH gradients formed by carrier ampholytes in a 
capillary [92]. It is important to note that pH plays a major role in CZE and should 
be well maintained [93]. Considerable protein adsorption must be considered when 
performing CIEF and CZE. The interaction of the analytes with the surface of the 
capillary may compromise the resolution, peak widths and shapes when using con-
ventional bare fused-silica capillaries. Minimizing adsorption can be done by using 
better coating material or using reagents that reduce adsorption [94]. A penetrated 
surface layer protein A from bacteria was reported as capillary coating. The coating 
could be used for over 100 injections without loss of separation performance [95]. 
Another study reported that adsorption still happened when using LPA-coated 
capillary [96].
CZE and CIEF are more often used for separations of charge variants induced by 
C-terminal lysine truncation, N-terminal pyroglutamate formation, sialylation and 
deamidation [97].
The direct coupling of CE with MS is technically challenging regarding the 
CE-MS interface [98]. A study demonstrated a successful attempt to directly couple 
CIEF with mass spectrometry for characterization of transtuzumab, bevacizumab, 
cetuzimab and infliximab by optimizing the reagent, liquid composition and 
enhanced sample mixture by glycerol to reduce non-CIEF electrophoretic mobility 
and band broadening [99]. A CZE method was developed for the intact analysis of 
recombinant human interferon-β1 (rhIFN-β1). The charged species due to deamida-
tion and sialylation were sufficiently separated. In contrast to dynamic polymeric 
coatings, such as polybrene or hydroxypropyl-methylcellulose, they covalently 
coated the bare-fused silica capillary with cross-linked polyethyleneimine (CPEI) 
to get positively charged surface, thus reducing the possibility of protein interaction 
with the coating. They then coupled this CZE to ESI-MS/MS and identified 138 
proteoforms, of which, 55 were quantified.
For the in-depth characterization of the composition of proteoforms of a 
therapeutic protein CE online-coupled to MS is a good option, if prior to the CE, 
the mixture of proteoforms has already been fractionated by LC using separation 
mechanisms orthogonal to the CE separation mechanism.
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Reversed phase liquid chromatography (RPLC) mainly exploits the differences in 
hydrophobic properties of molecules for their separation. Sample application onto 
RPLC columns is performed with eluents having a high content of water, support-
ing a high affinity of the molecules in the sample towards the stationary phase, 
which is hydrophobic. Elution is achieved with gradients increasing the concentra-
tion of organic solvents in the eluent. Coupling RPLC with the high sensitivity 
detectors can provide qualitative and quantitative information of the cleaved, 
modified proteoforms along with main form [68]. Ambrogelly et al. reported RPLC 
as a method giving a first-hand check of the product quality to help in optimizing 
the purification strategy [69]. When coupled to high resolution mass spectromet-
ric detection, RPLC also allows distinction of the major glycoforms. More than 
a decade ago, Dillion presented RPLC not only for determining the intact mAb 
glycosylation profile but only with the use of high temperature and organic solvents 
with high eluotropic strength coefficients [70]. Many advancement to conventional 
RPLC columns have come up in recent times to improve the separation of large 
therapeutic proteins at milder conditions [71].
The major concern in the use of RPLC for protein separations is the presence 
of organic solvents, which may precipitate proteins. Since precipitation will occur 
on the column, it is very difficult to recognize. In the case of proteoforms, it can 
be assumed that some may be more prone to precipitation than others. As a result, 
the chromatogram, in which signals from some but not all proteoforms are present, 
may be misinterpreted since the chromatogram is giving no information about the 
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for the analysis of proteoforms, because those species, which elute, are present in a 
liquid, which is optimal for electrospray ionization (ESI). Because of the problem 
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representative the TDMS chromatogram is regarding the original composition of 
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Elution modes of liquid chromatography: beside the different types of stationary 
phases, different elution modes are existing, which have an impact on the separation 
of molecules, namely isocratic elution, gradient elution (GE) and displacement elu-
tion (DE). DE is typically using the same sample application buffer and adsorption 
chromatography materials as gradient elution. In contrast to GE, DE is not using a 
salt gradient with an increasing concentration of a salt having a low affinity towards 
the stationary phase, but the elution buffer of DE is consisting of the sample 
application buffer, into which the displacer is added. The displacer ideally should 
have an affinity to the stationary phase higher than any of the sample components. 
After the sample application onto the column is finished, the eluent containing the 
displacer is immediately pumped onto the column. At the beginning, the displacer 
molecules are binding strongly to the top of the column, thereby displacing the 
sample component with the highest affinity. These sample components then dis-
place the sample components with a lower affinity and so on. By this process, bands 
are formed moving down the column, driven by the displacer. The DE is finished, as 
soon as the displacer has saturated the stationary phase of the column completely. 
Within a band a high purity of the component is achieved [72]. DE has been shown 
to be suitable for separation of complex mixture of tryptic peptides [73–75] and 
proteins [76–79]. One of the characteristics of DE is that DE has a different selectiv-
ity compared with GE [77]. This is one important argument for using DE for the 
separation of proteoforms. Thus, it is not surprising, that DE has been applied to the 
separation of proteoforms of therapeutic proteins successfully [46, 80–84].
Rational screening of parameters of liquid chromatography is recommended for 
optimal results of the separation of proteoforms. The first method describing 
multi-parallel high-throughput screening for parameters of liquid chromatography 
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was published 2002 by the group of Cramer [85]. In this case, the authors screened 
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for adsorption chromatography, independent of the elution mode [87]. The PPS 
was successfully applied for purification and identification of an angiotensin-II 
generating enzyme [88], and for screening for parameters for optimal displace-
ment chromatography of proteins [78, 79]. Rational screening was also used for 
developing a displacement chromatography of proteoforms of a recombinant 
protein with HIC [89].
4.2  Separation of proteoforms of therapeutic proteins with capillary 
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therapeutic protein CE online-coupled to MS is a good option, if prior to the CE, 
the mixture of proteoforms has already been fractionated by LC using separation 
mechanisms orthogonal to the CE separation mechanism.
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5. Conclusion
A huge progress has been made in the field of TDMS, allowing the identification 
and comprehensive analysis of the composition of atoms of proteoforms, especially 
if they are smaller than 30 kDa. TDMS analysis of larger proteoforms still is more 
challenging. However, until today the most critical point is the purification of a pro-
teoform towards near homogeneity or at least the significant reduction of complex-
ity of the sample, which is desorbed and ionized into a tandem mass spectrometer 
for TDMS. A low complexity of the composition of a protein mixture entering the 
MS still is mandatory for getting high quality spectra. Thus, efficient separation 
methods are needed for obtaining fractions with low complexity. For developing 
strategies for separating proteoforms, therapeutic proteins are well suited, however 
challenging because of their heterogeneity. In depth separation of the proteoforms 
of a therapeutic protein requires the combination of fractionation techniques based 
on orthogonal mechanisms. In addition, the combination of gradient chromatogra-
phy and displacement chromatography will add further opportunities for successful 
separations.
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Prolactin Proteoform Pattern 
Changed in Human Pituitary 




PRL gene-encoded prolactin is synthesized in the ribosome in the pituitary 
and then secretes into blood circulation to reach its target organ and exerts its 
biological roles, for example, involving in production, growth, development, 
immunoregulation, and metabolism. Multiple post-translational modifications 
and other unknown factors might be involved in this process to cause different 
prolactin proteoforms with differential isoelectric point (pI) and relative mass 
(Mr). Pituitary adenomas are the common disease occurring in pituitary organ 
to affect the endocrine system. Two-dimensional gel electrophoresis (2DGE) 
was used to separate prolactin proteoforms according to their pI and Mr, fol-
lowed by identification with Western blot and mass spectrometry (MS) analyses. 
Six prolactin proteoforms were identified in control pituitary tissues, and this 
prolactin proteoform pattern was significantly changed in different hormone 
subtypes of nonfunctional pituitary adenomas (NF−, LH+, FSH+, and LH+/
FSH+) and prolactinomas (PRL+). Further, bioinformatics analysis revealed 
that different prolactin proteoforms might bind to different short- or long-PRL 
receptor-mediated signaling pathways. These findings clearly demonstrated that 
prolactin proteoform pattern existed in human pituitary and changed in differ-
ent subtypes of pituitary adenomas. It is the scientific data to in-depth study 
prolactin functions, and to discover the prolactin proteoform biomarkers for 
PRL-related adenomas.
Keywords: prolactin proteoforms, pituitary, pituitary adenomas, nonfunctional 
pituitary adenomas, prolactinomas, biomarker
1. Introduction
Prolactin (PRL) is a multifunctional hormone which is synthesized and 
secreted by pituitary [1]. Human PRL gene is located on chromosome 6 [2]. The 
secretory mode of PRL is autocrine and paracrine [3], and the secretion of PRL is 
pulsating and circadian rhythm [4]. The concentration of PRL in human serum 
has a certain reference range, and when its concentration is too high or too low, 
it will have a certain impact on the body. Dopamine can inhibit the secretion of 
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secreted by pituitary [1]. Human PRL gene is located on chromosome 6 [2]. The 
secretory mode of PRL is autocrine and paracrine [3], and the secretion of PRL is 
pulsating and circadian rhythm [4]. The concentration of PRL in human serum 
has a certain reference range, and when its concentration is too high or too low, 
it will have a certain impact on the body. Dopamine can inhibit the secretion of 
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PRL, and there are cases where dopamine is used to treat hyperprolactinemia [1]. 
PRL’s biological functions include production, growth, development, immu-
noregulation, and metabolism [5, 6]. PRL can exert its biological functions 
only when it binds to its receptor and activates some signaling pathways [7]. 
According to the concept of proteoforms, a protein is defined as a set of proteo-
forms, due to different splicing, post-translational modifications (PTMs), and 
even unknown factors. Each proteoform has its own specific isoelectric point 
(pI) and molecular weight (Mr). For human PRL in the UniProt protein database, 
its pI is 6.5 and Mr is 25.88 kDa. However, Ben-Jonathan et al. found that human 
serum contained PRLs with Mr > 100, 40–60 and 16 kDa, besides the PRL with 
25.88 kDa [8]. Qian et al. found six PRLs with different pI and Mr in human 
pituitary tissues by two-dimensional gel electrophoresis (2DGE) and mass 
spectrometry (MS) [9]. Similarly, Zhan et al. found 24 growth hormone (GH) 
with different pI and Mr in human pituitary tissues by 2-DGE and MS [10]. A 
possible reason of this difference of pI and Mr in human PRL and GH is that they 
undergo PTMs or splicing [11]. A proteoform is a specific form that protein exerts 
its final functions, which is derived from a gene undergoing splicing, transcrip-
tion, translation, PTMs, translocation/re-distribution, and interaction with other 
molecules, etc. [12].
Recently 2DGE and MS have been recognized as high throughput and useful 
tool to study proteoforms [13–15]. 2DGE is able to separate each proteoform 
in the first dimension—isoelectric focusing (IEF) based on proteoform charge 
difference, and in the second dimension—sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE) based on proteoform relative mass 
difference [16]. Therefore, 2DGE achieves proteoform separation based on the 
difference in pI and Mr of proteoforms. And then the protein (exactly proteo-
forms) on the 2D gel is transferred to a polyvinylidene fluoride membrane for 
detection with a specific antibody. The immunoreactive positive 2D gel spots 
represent the proteoforms of a protein. The proteoform in each immunoreac-
tive positive spot was subjected to in-gel digestion with trypsin, and identifica-
tion with MS [17, 18]. MS is a key technique to identify organic molecules and 
analyze the extreme structure of certain substances [19]. Especially, top-down 
MS can quickly and extremely accurately determine the molecular weight of 
biomacromolecules, which enables proteomics research from protein general 
identification to advanced structural studies and protein-protein interaction 
studies. Moreover, with the development of MS technology, the accuracy and 
sensitivity of mass spectrometers have been greatly improved. MS has its 
absolute advantages in the use of less sample, faster analysis, and simultane-
ous separation and identification. Therefore, 2DGE in combination with MS is 
presenting as a super-high approach in separation and identification of large-
scale human proteoforms [14]. If the stable isotope labeling is introduced to 
prepare the protein sample prior to 2DGE-MS, then 2DGE-MS can also quantify 
the abundance of a proteoform between two given conditions such as tumors 
vs. controls [20].
Pituitary adenomas are the common disease occurred in pituitary organ to 
severely impact on the human endocrine system. PRL is an important pituitary 
hormone. It has important scientific merit in clarification of PRL proteoform 
pattern changed in different subtypes of pituitary adenomas compared to control 
pituitaries. This book chapter focuses on the PRL proteoforms in human pituitary 
and investigates the PRL proteoform pattern alterations in pituitary adenomas 
relative to controls, with 2DGE and MS. These findings provide the scientific data 
to in-depth study the PRL functions and to discover PRL proteoform biomarker for 
PRL-related adenomas.
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2. Methods
2.1 Pituitary tissue samples and preparation of protein samples
Eight human post-mortem control pituitary tissues, five PRL-positive prolactinoma 
tissues, three non-hormone expressed nonfunctional pituitary adenoma (NF-NFPA) 
tissues, three luteinizing hormone (LH)-positive NFPA tissues, three follicle-stimu-
lating hormone (FSH)-positive NFPA tissues, and three LH/FSH-both positive NFPA 
tissues were used to extract proteins, with the previously described procedure [21, 22]. 
The extracted protein of each tissue sample was used for 2DGE and MS analysis.
2.2 2DGE
A amount (70 μg) of proteins was diluted into 350 μL of protein sample buffer 
(7 mol/L urea, 2 mol/L thiourea, 40 g/L CHAPS, 100 mmol/L dithiothreitol (DTT), 
5 mol/L immobilized pH gradient (IPG) buffer pH 3–10 NL, and a trace of bromo-
phenol blue, followed by rehydration (18 h, 20°C) of precast IPG strips pH 3–10 NL 
(180 x 3 × 0.5 mm) in 18-cm IPG strip holder on an IPGphor instrument, and IEF 
(25°C) with parameters (Gradient 250 V and 1 h for 125 Vh, gradient at 1000 V and 
1 h for 500 Vh, gradient at 8000 V and 1 h for 4000 Vh, step-and-hold at 8000 and 
4 h for 32,000 Vh, step-and-hold at 500 V and 0.5 h for 250 Vh to achieve a total of 
36,875 Vh). After IEF, the proteins on IPG strip were reduced (15 min) with DTT, 
and alkylated with iodoacetamide, followed by separation with 12% SDS-PAGE 
(250 × 215 × 1.0 mm) in an Ettan DALT II system (GE Healthcare, up to 12 gels at 
a time) with a constant voltage (250 V, 360 min). All 2DGE-arrayed proteins were 
stained with silver-staining [23], and then digitized and analyzed with Discovery 
Series PDQuest 2D Gel Analysis software [24, 25]. Each sample was performed for 
3–5 times.
2.3 2DGE-based Western blot
The proteins in the 2D gel were partially transferred to a polyvinylidene fluoride 
(PVDF) membrane (0.8 mA/cm2 for 80 min) using Amersham Pharmacia Biotech 
Nova Blot semi-dry transfer instrument, followed by blocking (1 h, room tem-
perature) with bovine serum albumin (BSA), incubation (1 h, room temperature) 
with rabbit anti-hPRL antibodies, incubation (1 h, room temperature) with goat 
anti-rabbit alkaline phosphatase conjugated IgG, and visualization with 5-bromo-4-
chloro-3-indolyl phosphate. The detailed procedure was described previously [9].
2.4 In-gel digestion with trypsin and MS identification of PRL
The proteins in each Western blot-positive spot was performed in-gel digestion 
with trypsin, purification of tryptic peptides with ZipTipC18, followed by analysis 
with three types of MS instruments, including MALDI-TOF MS [24], LC-ESI-Q-IT 
MS [24], and MALDI-TOF-TOF MS [9]. The detailed procedure was described 
previously [9, 24]. The obtained peptide mass fingerprint (PMF) and tandem mass 
spectrometry (MS/MS) data were used to search Swiss-Prot human database for 
protein determination and PTM analysis.
2.5 Bioinformatics and statistical analysis
The phosphorylation sites, O-glycosylation sites, and N-glycosylation 
sites in the PRL amino acid sequence were predicted with NetPhos 3.1 Server 
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relative to controls, with 2DGE and MS. These findings provide the scientific data 
to in-depth study the PRL functions and to discover PRL proteoform biomarker for 
PRL-related adenomas.
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2. Methods
2.1 Pituitary tissue samples and preparation of protein samples
Eight human post-mortem control pituitary tissues, five PRL-positive prolactinoma 
tissues, three non-hormone expressed nonfunctional pituitary adenoma (NF-NFPA) 
tissues, three luteinizing hormone (LH)-positive NFPA tissues, three follicle-stimu-
lating hormone (FSH)-positive NFPA tissues, and three LH/FSH-both positive NFPA 
tissues were used to extract proteins, with the previously described procedure [21, 22]. 
The extracted protein of each tissue sample was used for 2DGE and MS analysis.
2.2 2DGE
A amount (70 μg) of proteins was diluted into 350 μL of protein sample buffer 
(7 mol/L urea, 2 mol/L thiourea, 40 g/L CHAPS, 100 mmol/L dithiothreitol (DTT), 
5 mol/L immobilized pH gradient (IPG) buffer pH 3–10 NL, and a trace of bromo-
phenol blue, followed by rehydration (18 h, 20°C) of precast IPG strips pH 3–10 NL 
(180 x 3 × 0.5 mm) in 18-cm IPG strip holder on an IPGphor instrument, and IEF 
(25°C) with parameters (Gradient 250 V and 1 h for 125 Vh, gradient at 1000 V and 
1 h for 500 Vh, gradient at 8000 V and 1 h for 4000 Vh, step-and-hold at 8000 and 
4 h for 32,000 Vh, step-and-hold at 500 V and 0.5 h for 250 Vh to achieve a total of 
36,875 Vh). After IEF, the proteins on IPG strip were reduced (15 min) with DTT, 
and alkylated with iodoacetamide, followed by separation with 12% SDS-PAGE 
(250 × 215 × 1.0 mm) in an Ettan DALT II system (GE Healthcare, up to 12 gels at 
a time) with a constant voltage (250 V, 360 min). All 2DGE-arrayed proteins were 
stained with silver-staining [23], and then digitized and analyzed with Discovery 
Series PDQuest 2D Gel Analysis software [24, 25]. Each sample was performed for 
3–5 times.
2.3 2DGE-based Western blot
The proteins in the 2D gel were partially transferred to a polyvinylidene fluoride 
(PVDF) membrane (0.8 mA/cm2 for 80 min) using Amersham Pharmacia Biotech 
Nova Blot semi-dry transfer instrument, followed by blocking (1 h, room tem-
perature) with bovine serum albumin (BSA), incubation (1 h, room temperature) 
with rabbit anti-hPRL antibodies, incubation (1 h, room temperature) with goat 
anti-rabbit alkaline phosphatase conjugated IgG, and visualization with 5-bromo-4-
chloro-3-indolyl phosphate. The detailed procedure was described previously [9].
2.4 In-gel digestion with trypsin and MS identification of PRL
The proteins in each Western blot-positive spot was performed in-gel digestion 
with trypsin, purification of tryptic peptides with ZipTipC18, followed by analysis 
with three types of MS instruments, including MALDI-TOF MS [24], LC-ESI-Q-IT 
MS [24], and MALDI-TOF-TOF MS [9]. The detailed procedure was described 
previously [9, 24]. The obtained peptide mass fingerprint (PMF) and tandem mass 
spectrometry (MS/MS) data were used to search Swiss-Prot human database for 
protein determination and PTM analysis.
2.5 Bioinformatics and statistical analysis
The phosphorylation sites, O-glycosylation sites, and N-glycosylation 
sites in the PRL amino acid sequence were predicted with NetPhos 3.1 Server 
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(http://www.cbs.dtu.dk/services/NetPhos) [26, 27], NetOGlyc 4.0 Server (http://
www.cbs.dtu.dk/services/NetOGlyc) [28], and NetNGlyc 1.0 Server (http://www.cbs.
dtu.dk/services/NetNGlyc) [29]. The PRL proteoform pattern changes were tested 
with the Chi-square test among different subtypes of pituitary adenomas (p < 0.05).
3. Results and discussion
3.1 The amino acid sequences of human PRL prohormone and mature PRL
In human pituitary, the PRL prohormone is synthesized in the ribosome, with 
227 amino acids (position 1–227; 25.9 kDa), containing a signal peptide (posi-
tion 1–28) (Table 1), which was assigned with Swiss-Prot accession No. P01236. 
However, the mature human PRL only contains 199 amino acids (position 29–227; 
22.9 kDa), which removed the signal peptide (position 1–28), and secreted into the 
circulation system to bind to its target organ for exerting PRL function.
3.2 PRL proteoform pattern in human pituitaries
The PRL proteoform pattern was found in human pituitaries. Qian et al. [9] found 
six PRL proteoforms with 2DGE in human pituitaries and then verified four of six PRL 
proteoforms with 2DGE-based Western blot in human pituitaries (Figures 1 and 2). 
The pI and Mr of these PRL proteoforms are slightly different. Each PRL proteoform 
was digested with trypsin, and followed by MS and MS/MS analysis (Figures 3 and 4). 
 The characteristic tryptic peptide are calculated to determine whether the signal 
peptide (position 1–28) in each PRL proteoform (Table 2), which was compared to the 
observed ions of each PRL proteoform. It found all PRL proteoforms all contained the 
tryptic peptide sequence MNIKGSPWK (position 1–9), which clearly demonstrated 
that six PRL proteoforms are all PRL prohormone, but not mature PRL.
3.3  PRL proteoform changes in human pituitary adenomas compared to 
controls
The PRL proteoform pattern changed in different subtypes of pituitary adeno-
mas compared to control pituitaries (Table 3). The ratio of each subtype of pituitary 
10 20 30 40 50
MNIKGSPWKG SLLLLLVSNL LLCQSVAPLP ICPGGAARCQ VTLRDLFDRA
60 70 80 90 100
VVLSHYIHNL SSEMFSEFDK RYTHGRGFIT KAINSCHTSS LATPEDKEQA
110 120 130 140 150
QQMNQKDFLS LIVSILRSWN EPLYHLVTEV RGMQEAPEAI LSKAVEIEEQ
160 170 180 190 200
TKRLLEGMEL IVSQVHPETK ENEIYPVWSG LPSLQMADEE SRLSAYYNLL
210 220
HCLRRDSHKI DNYLKLLKCR IIHNNNC
Reproduced from Qian et al. [9], with copyright permission from Frontiers in open access article, copyright 2018.
Table 1. 
Human PRL prohormone amino acid sequence (position 1–227) and mature PRL (position 29–227). The signal 
peptide is position 1-28 in the bold letters.
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adenoma relative to control pituitaries was decreased or unchanged. The propor-
tional ratio of six PRL proteoforms among five subtypes of pituitary adenomas was 
changed (Table 4 and Figure 5). In FSH+/LH+ and PRL+ pituitary adenomas, the 
proportion of PRL proteoform v1 is the largest. In FSH+ pituitary adenoma, the pro-
portion of PRL proteoform v5 is the largest. The PRL proteoform changes suggest 
their scientific merit for clinical application.
3.4  Bioinformatics prediction of potential factors to form PRL proteoforms and 
pathway networks
PRL is a hormone which is secreted by pituitary gland. PRL has a variety of 
biological functions. Only when it reaches a specific target organ and binds to its 
receptor can it play its biological function (Figure 6). PRL can bind to short PRL 
receptor or long PRL receptor and then plays its biological functions. The long or 
short PRL receptors definitely bind to different PRL proteoforms. PRL proteoforms 
are definitely derived from a PRL gene undergoing splicing, transcription, transla-
tion, PTMs, translocation/re-distribution, and interaction with other molecules, 
etc. Therefore, phosphorylation sites in hPRL (position 1–227) were predicted 
Figure 1. 
PRL proteoform pattern in human pituitaries with a 2DGE gel image. Reproduced from Qian et al. [9], with 
copyright permission from Frontiers in open access article, copyright 2018.
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with NetPhos 3.1 Server with a score more than 0.5. It obtained 22 statistically 
significantly phosphorylation sites in hPRL (position 1–227). N-glycosylation sites 
in hPRL (position 1–227) were predicted with NetNGlyc 1.0 Server with score 
more than 0.5. It obtained 10 statistically significant N-glycosylation sites in hPRL 
(position 1–227). O-glycosylation sites in hPRL (position 1–227) were predicted 
with NetOGlyc 4.0 Server with score more than 0.5. It obtained six statistically 
significant O-glycosylation sites in hPRL (position 1–227). These data suggest that 
PTMs such as phosphorylation and glycosylation might be the important reason to 
cause the PRL proteoforms.
Figure 2. 
Verification of PRL proteoforms with 2DGE-based Western blot in human pituitaries. (A) Western blot image. 
(B) Silver-stained image. Reproduced from Qian et al. [9], with copyright permission from Frontiers in open 
access article, copyright 2018.
Figure 3. 
PMF analysis of hPRL that was contained in spot v6. Reproduced from Qian et al. [9], with copyright 
permission from Frontiers in open access article, copyright 2018.
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3.5 Potential clinical application of PRL proteoform pattern
Prolactin synthesized in the ribosome in the pituitary secretes into blood 
circulation to reach its target organ and exert its biological roles, which is closely 
associated with multiple physiological and pathological processes, including 
pituitary adenomas. This study found six PRL proteoforms with different with 
differential isoelectric point (pI) and relative mass (Mr) in control pituitary tissues, 
which were identified with 2DGE coupled with Western blot and MS. This prolactin 
Figure 4. 
MS/MS analysis of the tryptic peptide 118SWNEPLYHLVTEVR131 that was derived from PRL in spot v6. 




Position Characteristic tryptic peptide sequence Observed 
[M + H]+
505.2803 1–4 MNIK −
1060.5608 1–9 MNIKGSPWK +
3930.1893 1–38 MNIKGSPWKGSLLLLLVSNLLLCQSVAPLPICPGGAAR −
574.2983 5–9 GSPWK −
3443.9268 5–38 GSPWKGSLLLLLVSNLLLCQ SVAPLPICPGGAAR −
2888.6463 10–38 GSLLLLLVSNLLLCQSVAPL PICPGGAAR −
3589.0154 10–44 GSLLLLLVSNLLLCQSVAPL PICPGGAARCQVTLR −
954.5189 29–38 LPICPGGAAR −
1654.8879 29–44 LPICPGGAARCQVTLR −
2301.1954 29–49 LPICPGGAARCQVTLRDLFD R −
+, this peptide ion was observed with mass spectrometry in each MS spectrum.  
−, this peptide was not observed with mass spectrometry.  
Reproduced from Qian et al. [9], with copyright permission from Frontiers in open access article, copyright 2018.
Table 2. 
Characteristic tryptic peptides to determine signal peptide (position1–28) within human PRL proteoforms in 
human pituitary.
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Table 2. 
Characteristic tryptic peptides to determine signal peptide (position1–28) within human PRL proteoforms in 
human pituitary.
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PRL proteoform NF− (%) FSH+/LH+ (%) FSH+ (%) LH+ (%) PRL+ (%)
V1 2.64 53.34 24.24 9.45 40.48
V2 1.56 2.03 0.52 3.08 11.90
V3 0.31 6.57 7.66 19.65 11.91
V4t 31.83 10.14 9.18 15.08 11.90
V5 31.83 10.52 52.47 27.53 11.91
V6 31.83 17.40 5.93 25.21 11.90
Total 100.00 100.00 100.00 100.00 100.00
Reproduced from Qian et al. [9], with copyright permission from Frontiers in open access article, copyright 2018.
*Chi-square test = 360.606, p = 0.000 (p < 0.01) among five subtypes of pituitary adenomas.
Table 4. 





















V1 P01236 6.1 26.0 −8.3 −99.9 −46.2 −12.6 −3.4
V2a P01236 6.3 26.4 −4.9 −3.8 1 −4.1 1
V3 P01236 6.3 27.9 1 −12.3 −14.6 −26.2 1
V4b P01236 6.5 26.1 −100 −19.0 −17.6 −20.1 1
V5 P01236 6.8 25.9 −100 −19.7 −100 −36.7 1
V6 P01236 6.7 25.9 −100 −32.6 −11.3 −33.6 1
Modified from Qian et al. [9], with copyright permission from Frontiers in open access article, copyright 2018.
aCharacterized with LC-ESI MS/MS.
bCharacterized with LC-ESI-MS/MS and MALDI-TOF PMF.
All other proteins were characterized with MALDI-TOF PMF. Con, control; −, decreased relative to controls; −100, 
lost relative to controls; 1, no change relative to controls; Mr, kDa.
Table 3. 
Prolactin proteoform pattern changed in different subtypes of pituitary adenomas compared to control 
pituitaries.
Figure 5. 
Proportional ratio changes of PRL proteoforms among five subtypes of pituitary adenomas. Reproduced from 
Qian et al. [9], with copyright permission from Frontiers in open access article, copyright 2018.
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proteoform pattern was significantly changed among different hormone-subtypes 
of nonfunctional pituitary adenoma (NF−, LH+, FSH+, and LH+/FSH+) and prolacti-
noma (PRL+) tissues. This result suggests the potentially important clinical value of 
serum PRL proteoforms. The reason is that pituitary tissues are impossible to obtain 
for clinical diagnosis, and prolactin must secrete into blood to exert its biological 
roles, we strongly believe serum PRL proteoforms exist and the serum PRL pro-
teoform pattern changes among different pituitary adenomas. Therefore, we will 
further analyze serum PRL proteoform pattern changes among different subtypes 
of pituitary adenomas, and develop the PRL proteoform pattern as biomarker for 
prediction, diagnosis, or prognostic assessment of pituitary adenoma occurrence, 
progression, and prognosis.
4. Conclusions
Six PRL proteoforms were identified in human pituitary tissue with 2DGE and 
MS analyses, and four of six PRL proteoforms were validated with 2DGE-based 
Western blot, MS, and MS/MS analyses. There were significant differences in PRL 
proteoform pattern among five different subtypes of pituitary adenomas (LH+, 
NF−, FSH+, FSH+/LH+, and PRL+) (P < 0.05). Moreover, MS analysis revealed that 
six PRL proteoforms are PRL prohormone. PRL proteoforms might be derived from 
PTMs such as phosphorylation, deamidation, and glycosylation. Further, different 
PRL proteoforms might bind to different PRL receptors to produce different physi-
ological functions. These findings provide scientific basis for in-depth understand-
ing of pituitary adenomas, and help develop biomarkers for treatment of pituitary 
adenoma patients. The serum PRL proteoform pattern has important clinical 
application value for prediction, diagnosis, and prognostic assessment of pituitary 
adenomas.
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Figure 6. 
PRL proteoform-driven signaling pathway via the short or long PRL receptors. Reproduced from Qian et al. 
[9], with copyright permission from Frontiers in open access article, copyright 2018.
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Proteoforms in Acute Leukemia: 
Evaluation of Age- and  
Disease-Specific Proteoform 
Patterns
Fieke W. Hoff, Anneke D. van Dijk and Steven M. Kornblau
Abstract
Acute leukemia are a heterogeneous group of malignant diseases of the bone 
marrow that occur at all ages. Acute lymphoid leukemia (ALL) accounts for about 
80% of all pediatric leukemia patients, whereas acute myeloid leukemia (AML) is 
more common in adults compared to pediatric patients. Despite similar patterns in the 
pathogenesis of acute leukemia in children and adults, clinical outcome in response to 
therapy differs substantially. Studying proteoforms in acute leukemia in children and 
adults, might identify similarities and differences in crucial signaling pathways that 
play a key role in the development or progression of the disease. In this chapter we will 
discuss how the study of proteoforms in acute leukemia could potentially contribute 
to a better understanding of the leukemogenesis, can help to identify effective targets 
for specific targeted treatment approaches in different subgroups of age and disease, 
and could aid the development of reliable biomarkers for prognostic stratification.
Keywords: acute myeloid leukemia, acute lymphoblastic leukemia, proteoforms, 
RPPA, pediatrics
1. Introduction
Acute leukemia forms a group of rapidly progressing malignant diseases char-
acterized by a block in the differentiation and an uncontrolled clonal proliferation 
of abnormal hematopoietic progenitor cells in the bone marrow and the peripheral 
blood [1, 2]. This accumulation of immature cells (“blasts”) interferes with the pro-
duction of normal blood cells, causing neutropenia, thrombocytopenia and anemia. 
According to the lineage of origin of the progenitor cells, the common lymphoid or 
the common myeloid, acute leukemia can roughly be classified into acute lympho-
blastic leukemia (ALL) and acute myeloid leukemia (AML).
Acute leukemia patients are diagnosed using morphologic, cytochemical and 
immunophenotypic methods, and are further sub-classified by chromosomal 
analysis and the presence or absence of somatically acquired gene mutations. While 
classification allows for prediction of outcome, the outcome risk of a large group 
of patients is still difficult to define. In addition, treatment options are expanding 
that treat patients based on their genetic abnormalities (in particular in the adult 
population), but so far most genetic abnormalities are not yet targetable, and most 
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blood [1, 2]. This accumulation of immature cells (“blasts”) interferes with the pro-
duction of normal blood cells, causing neutropenia, thrombocytopenia and anemia. 
According to the lineage of origin of the progenitor cells, the common lymphoid or 
the common myeloid, acute leukemia can roughly be classified into acute lympho-
blastic leukemia (ALL) and acute myeloid leukemia (AML).
Acute leukemia patients are diagnosed using morphologic, cytochemical and 
immunophenotypic methods, and are further sub-classified by chromosomal 
analysis and the presence or absence of somatically acquired gene mutations. While 
classification allows for prediction of outcome, the outcome risk of a large group 
of patients is still difficult to define. In addition, treatment options are expanding 
that treat patients based on their genetic abnormalities (in particular in the adult 
population), but so far most genetic abnormalities are not yet targetable, and most 
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drugs that enter clinical trials rely on the increased abundance or altered activity of 
proteins, namely specific proteoforms, instead of the genetic lesion itself.
Proteoforms are defined as different forms of a protein derived from a single 
gene, and include all forms of genetic variation (e.g. amino acid variation), alterna-
tive splicing, and post-translational modifications (PTM). This means that one 
transcribed gene can lead to a variety of protein structures, and that the biologi-
cal function of the final proteoform, as well as the cellular localization, binding 
partners and kinetics can vary greatly. As this suggests that gene sequences do not 
accurately predict the expression of a protein or whether the protein is stable or 
functional, it is not surprising that transcriptome data only correlates for about 
17–40% with protein abundance [3–5]. Proteoforms are the basic units of a pro-
teome. We believe that the study of proteoforms is an essential strategy to reveal 
cell dependencies and their underlying mechanism, and that this could add in the 
process of risk stratification and could identify novel therapeutic targets in highly 
complex diseases such as acute leukemia. Moreover, as the cure rates between ALL 
and AML, and between children and adults markedly differ, a direct comparison of 
the leukemic proteoforms between those patients, may aid to unravel the biological 
pathogenesis, and reveal similarities and dissimilarities that can propose therapeu-
tics that target these proteoforms in one disease, that could also be effective in an 
otherwise disparate leukemia that shares protein patterns.
2. Acute leukemia
2.1 Acute lymphoblastic leukemia
ALLs are neoplasms composed of immature B (pre-B), T (pre-T) or NK-cells 
that are referred as (“lymphoblasts”), of which the majority is pre-B ALL (85–90% 
in children vs. 75% in adults) [1]. It is the most common cancer in children and 
accounts for a quarter of all childhood malignancies. Although there are as many 
adults with ALL as there are children with the disease, the relative frequency in 
adults is much lower. Worldwide, the overall incidence is approximately 1–2 per 
100.000 people, with a peak incidence occurring in childhood and a second peak 
above the age of 50 years [6].
2.1.1 Cytogenetic abnormalities
Chromosomal aberrations are the hallmark of ALL and are often used to catego-
rize patients. In B-ALL, recurrent chromosomal abnormalities are found in 80% of 
the patients, including numerical and structural changes as translocations, deletions 
and inversions. There are substantial differences in the frequencies of occurring of 
cytogenetic abnormalities between children and adults [1, 7–10]. For instance, the 
translocation 9;22 [BCR-ABL1] is observed in 2–5% of the children compared to in 
30% of the adults, whereas the translation 12;21 [ETV6-RUNX1] is observed in 25% 
of the pediatric patients versus 3% in adult population. The hyperdiploid (gain of 
chromosomes) karyotype is present in 30–40% of the children compared to 3% in 
adults. Finally, translocation 4;11 resulting in the MLL-AF4 fusion gene, is detected 
in 60–80% of the infants (younger than 1 year old), whereas it is seen in only 2% of 
the patients up to 15 years and rare in adults. Hypodiploidy (loss of chromosomes) 
occurs in 5–6% of the ALL patients, independent of age.
Chromosomal translations occur less frequently in T-ALL compared to B-ALL 
(approximately 50–60%) and unlike in B-ALL their prognostic impact is not well 
defined and they are not used for risk stratification [10]. They are involved in both 
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the T-cell receptor and the non-T-cell receptor loci on the chromosome or aberrant 
expression of the transcription factor oncogenes. There is less association with age [8].
2.1.2 Prognosis
Survival in children with ALL is much better compared to adults, with the 
exception of infant ALL. In 60–80% of the cases, infant ALL is characterized by 
translocations involving 11q23, affecting the KMT2A gene. Aberrant KMT2A in 
ALL is associated with a high rate of early treatment failure and a very poor out-
come (long-term event-free survival of 28–45%), even when treated with more 
aggressive chemotherapy regimens [11, 12]. Historically, pediatric T-ALL was 
considered as high-risk disease. With the introduction of therapy intensification in 
T-cell ALL, this has changed to outcomes comparable to B-cell ALL, resulting in a 
five-year OS rate of more than 90% [13]. However, within certain high-risk sub-
groups (e.g. infants or children ≥10 years of age), 25–30% still experience relapse, 
which has a dismal outcome even with hematopoietic stem cell transplantation. 
Death resulting from treatment toxicity remains a challenge with an estimated 
10-year cumulative incidence of treatment-related death of 2.9% [14].
Survival for ALL in adults is around 45%, but patients above the age of 60 
suffer from inferior outcomes with only 10–15% long-term survival [10]. This is, at 
least partially, due to higher risk of medical comorbidities, the inability to tolerate 
standard chemotherapy regimens, and age-related unfavorable intrinsic biology 
such as Philadelphia chromosome positive, hypodiploidy and complex karyotype. 
However, as even the adolescents and young adults who lack medical comorbidities 
do significantly worse compared to their younger counterparts, the contribution of 
the different underlying biology should not be underestimated [8].
2.2 Acute myeloid leukemia
In general, patients with AML have similar signs and symptoms as patients with 
ALL which mainly includes symptoms related to (pan)cytopenia. AML is the most 
common acute leukemia in adults, whereas it is relatively rare in children (account-
ing for only 10% of the acute leukemia) [15]. Overall, AML occurs in 3–5 cases per 
100.000 people, and the incidence strongly increases with age.
2.2.1 Cytogenetic and molecular abnormalities
AML is a very heterogeneous disease and the identification of AML-associated 
chromosomal translocations and inversions have led to the current 2016 World 
Health Organization (WHO) classification system [16]. In this classification, 
eight recurrent genetic abnormalities (e.g. translocation (15;17) [PML-RARA], 
translocation (8;21) [RUNX1-RUNX1T1], inversion (16) or translocation (16;16) 
[CBFB-MYH1], translocation (9;11) [MLLT3-KMT2A], and translocation (9;22) 
[BCR-ABL1]) and their variants are included. In approximately 50 percent of 
patients, no cytogenetic abnormalities will be present, referred to as “normal 
karyotype” [17]. Additional classification in AML is provided by detection of one 
or more recurrent genetic mutations, with NPM1, FLT3, IDH1, IDH2, RUNX1 and 
CEBPA most studied.
Recently, the Therapeutically Applicable Research to Generate Effective 
Treatments (TARGET) study has presented the molecular landscape of nearly 1000 
pediatric AML patients that participated in several Children’s Oncology Group 
(COG) clinical trials [18]. Like adult AML, they found that pediatric AML has one 
of the lowest rates of mutations as compared to other cancers as recognized by The 
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drugs that enter clinical trials rely on the increased abundance or altered activity of 
proteins, namely specific proteoforms, instead of the genetic lesion itself.
Proteoforms are defined as different forms of a protein derived from a single 
gene, and include all forms of genetic variation (e.g. amino acid variation), alterna-
tive splicing, and post-translational modifications (PTM). This means that one 
transcribed gene can lead to a variety of protein structures, and that the biologi-
cal function of the final proteoform, as well as the cellular localization, binding 
partners and kinetics can vary greatly. As this suggests that gene sequences do not 
accurately predict the expression of a protein or whether the protein is stable or 
functional, it is not surprising that transcriptome data only correlates for about 
17–40% with protein abundance [3–5]. Proteoforms are the basic units of a pro-
teome. We believe that the study of proteoforms is an essential strategy to reveal 
cell dependencies and their underlying mechanism, and that this could add in the 
process of risk stratification and could identify novel therapeutic targets in highly 
complex diseases such as acute leukemia. Moreover, as the cure rates between ALL 
and AML, and between children and adults markedly differ, a direct comparison of 
the leukemic proteoforms between those patients, may aid to unravel the biological 
pathogenesis, and reveal similarities and dissimilarities that can propose therapeu-
tics that target these proteoforms in one disease, that could also be effective in an 
otherwise disparate leukemia that shares protein patterns.
2. Acute leukemia
2.1 Acute lymphoblastic leukemia
ALLs are neoplasms composed of immature B (pre-B), T (pre-T) or NK-cells 
that are referred as (“lymphoblasts”), of which the majority is pre-B ALL (85–90% 
in children vs. 75% in adults) [1]. It is the most common cancer in children and 
accounts for a quarter of all childhood malignancies. Although there are as many 
adults with ALL as there are children with the disease, the relative frequency in 
adults is much lower. Worldwide, the overall incidence is approximately 1–2 per 
100.000 people, with a peak incidence occurring in childhood and a second peak 
above the age of 50 years [6].
2.1.1 Cytogenetic abnormalities
Chromosomal aberrations are the hallmark of ALL and are often used to catego-
rize patients. In B-ALL, recurrent chromosomal abnormalities are found in 80% of 
the patients, including numerical and structural changes as translocations, deletions 
and inversions. There are substantial differences in the frequencies of occurring of 
cytogenetic abnormalities between children and adults [1, 7–10]. For instance, the 
translocation 9;22 [BCR-ABL1] is observed in 2–5% of the children compared to in 
30% of the adults, whereas the translation 12;21 [ETV6-RUNX1] is observed in 25% 
of the pediatric patients versus 3% in adult population. The hyperdiploid (gain of 
chromosomes) karyotype is present in 30–40% of the children compared to 3% in 
adults. Finally, translocation 4;11 resulting in the MLL-AF4 fusion gene, is detected 
in 60–80% of the infants (younger than 1 year old), whereas it is seen in only 2% of 
the patients up to 15 years and rare in adults. Hypodiploidy (loss of chromosomes) 
occurs in 5–6% of the ALL patients, independent of age.
Chromosomal translations occur less frequently in T-ALL compared to B-ALL 
(approximately 50–60%) and unlike in B-ALL their prognostic impact is not well 
defined and they are not used for risk stratification [10]. They are involved in both 
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the T-cell receptor and the non-T-cell receptor loci on the chromosome or aberrant 
expression of the transcription factor oncogenes. There is less association with age [8].
2.1.2 Prognosis
Survival in children with ALL is much better compared to adults, with the 
exception of infant ALL. In 60–80% of the cases, infant ALL is characterized by 
translocations involving 11q23, affecting the KMT2A gene. Aberrant KMT2A in 
ALL is associated with a high rate of early treatment failure and a very poor out-
come (long-term event-free survival of 28–45%), even when treated with more 
aggressive chemotherapy regimens [11, 12]. Historically, pediatric T-ALL was 
considered as high-risk disease. With the introduction of therapy intensification in 
T-cell ALL, this has changed to outcomes comparable to B-cell ALL, resulting in a 
five-year OS rate of more than 90% [13]. However, within certain high-risk sub-
groups (e.g. infants or children ≥10 years of age), 25–30% still experience relapse, 
which has a dismal outcome even with hematopoietic stem cell transplantation. 
Death resulting from treatment toxicity remains a challenge with an estimated 
10-year cumulative incidence of treatment-related death of 2.9% [14].
Survival for ALL in adults is around 45%, but patients above the age of 60 
suffer from inferior outcomes with only 10–15% long-term survival [10]. This is, at 
least partially, due to higher risk of medical comorbidities, the inability to tolerate 
standard chemotherapy regimens, and age-related unfavorable intrinsic biology 
such as Philadelphia chromosome positive, hypodiploidy and complex karyotype. 
However, as even the adolescents and young adults who lack medical comorbidities 
do significantly worse compared to their younger counterparts, the contribution of 
the different underlying biology should not be underestimated [8].
2.2 Acute myeloid leukemia
In general, patients with AML have similar signs and symptoms as patients with 
ALL which mainly includes symptoms related to (pan)cytopenia. AML is the most 
common acute leukemia in adults, whereas it is relatively rare in children (account-
ing for only 10% of the acute leukemia) [15]. Overall, AML occurs in 3–5 cases per 
100.000 people, and the incidence strongly increases with age.
2.2.1 Cytogenetic and molecular abnormalities
AML is a very heterogeneous disease and the identification of AML-associated 
chromosomal translocations and inversions have led to the current 2016 World 
Health Organization (WHO) classification system [16]. In this classification, 
eight recurrent genetic abnormalities (e.g. translocation (15;17) [PML-RARA], 
translocation (8;21) [RUNX1-RUNX1T1], inversion (16) or translocation (16;16) 
[CBFB-MYH1], translocation (9;11) [MLLT3-KMT2A], and translocation (9;22) 
[BCR-ABL1]) and their variants are included. In approximately 50 percent of 
patients, no cytogenetic abnormalities will be present, referred to as “normal 
karyotype” [17]. Additional classification in AML is provided by detection of one 
or more recurrent genetic mutations, with NPM1, FLT3, IDH1, IDH2, RUNX1 and 
CEBPA most studied.
Recently, the Therapeutically Applicable Research to Generate Effective 
Treatments (TARGET) study has presented the molecular landscape of nearly 1000 
pediatric AML patients that participated in several Children’s Oncology Group 
(COG) clinical trials [18]. Like adult AML, they found that pediatric AML has one 
of the lowest rates of mutations as compared to other cancers as recognized by The 
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Cancer Genome Atlas, suggesting that the number of recognized recurrent muta-
tions in AML alone is not sufficient to explain its heterogeneity. They demonstrated 
that the landscape of somatic variants in pediatric AML was markedly different 
from that reported in adults, highlighting the need for and facilitate the develop-
ment of age-tailored targeted therapies for the treatment of pediatric AML [19, 20].
2.2.2 Prognosis
Among adult patients who are under 60 years of age, AML can be cured in 
35–40% of the patients, whereas the survival rates of patients older than 60 is only 
5–15%. For older patients who are unable to receive intensive chemotherapy without 
acceptable side effects the prognosis is even more dismal, with a median survival 
of only 5–10 months [2]. Survival rates in the pediatric population, have improved 
greatly, although OS rates of 65–70% are still much lower than that for pediatric 
ALL [21].
3. Proteome differs from transcriptome
The human genome is the total amount of DNA that each cell in the body 
contains, including an estimated of 30,000–40,000 protein-coding genes. While 
the basic dogma of biology formerly was that DNA was transcribed into messenger 
RNA, which is then translated into proteins, and that mRNA levels could be used to 
predict protein abundance, it becomes more and more clear that this is overly sim-
plistic due to our expanding knowledge of the effects of epigenetics, environmental 
influences, mRNA editing, alternative splicing and noncoding RNAs on gene 
expression. For instance, coding single-nucleotide polymorphisms and mutations 
can affect the final protein sequence and function, and based on endogenous prote-
olysis and mRNA splicing, different isoforms can be generated from the same set of 
nucleotides. Additionally, after translation of the RNA transcript, proteins undergo 
multiple modifications affecting the protein function, localization, lifespan and 
activity. Together this results in up to a million of proteoforms.
One of the first studies back in 1999, that compared a limited number of mRNA 
and proteins using Saccharomyces cerevisiae, already concluded that the correlation 
between both was only 0.36 [4, 22]. And, even with the significant improvements in 
high-throughput genomic and proteome approaches, this fundamental observation 
continues to be widely, though not universally, supported, as most studies nowadays 
still show a correlation coefficient that varies between 0.17 and 0.40. Per example, 
Mun et al. recently performed correlation analysis of mRNA and protein log2-fold 
changes between gastric cancer tumor samples and adjacent normal tissues using 
6803 genes with protein and mRNA abundances available in at least 30% (≥24) of 
the patients. Of the 6803 genes, only 34.3% showed significant (FDR < 0.01) positive 
correlation with an average correlation coefficient of 0.28 [23]. Zang et al., per-
formed an integrated proteogenomic analyses human colon and rectal cancer samples 
and while 89% of the samples showed significant positive mRNA-protein correlation 
(of which only 32% was significantly correlated), the average correlation between 
messenger RNA transcript abundance and protein abundance was only 0.23 [24].
4. Age-associated proteoforms in acute leukemia
Aforementioned, the functional variant of a protein, the proteoform, is defined 
by genetics, mRNA editing, and PTMs. In particular in ALL, that peaks between 2 
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and 5 years of age followed by a gradual increase in the older patients, is it suggested 
that different combinations of genetic factors (resulting in different proteoforms) 
contribute to leukemogenesis at different ages. In order to answer the question why 
genes are differentially expressed upon age, a closer look at biological processes that 
influence the final proteoform production via pre-translational modifications may 
help. Here we will discuss a few examples of how these differ between younger and 
older patients with acute leukemia.
4.1 Genetic variants
Emerging genome wide sequencing techniques identified disease and age-spe-
cific gene variants in acute leukemia. For example, Perez-Andreu et al. discovered a 
single nucleotide polymorphism (SNP), a variant of the coding region of the DNA, 
of GATA3 on 10p14 that was associated with the susceptibility to ALL in adolescents 
and young adults, and that progressively increased with age [25]. Furthermore, 
genomic variants that occur in both pediatric and adult leukemia sometimes display 
a different phenotype at the protein level. As shown by Zuurbier et al., loss of PTEN 
protein due to the production of an unstable and truncated proteoform caused by 
a frameshift mutation or genomic deletion is a frequently seen in T-cell ALL (pre-
dominantly in pediatric T-ALL). PTEN is often recognized as a tumor suppressor, 
but its behavior and relation to outcome is highly context dependent. PTEN abnor-
malities may impact NOTCH1 and, in a cohort of PTEN mutated pediatric T-ALL 
patients (with loss of PTEN protein) that lacked the NOTCH1 activating mutations, 
had significantly fewer relapses compared to patients with activated PTEN and 
NOTCH1 [26]. In contrast, another study showed that PTEN mutations without 
NOTCH1 abnormalities were associated with poor prognosis in adults [37]. Thus, 
genomic mutations within the same gene, do not always produce the same proteo-
form with the same function. Mutations can create a proteoform with a completely 
different function and can convert a protein from a tumor suppressor into a tumor 
driver [27]. Although, genome wide studies are very meaningful in detection of 
conditions specific to age and disease, but the net effect on the cell largely depends 
on the production of the final proteoform (tumor suppressor or tumor driver) and 
the pathways they act in.
4.2 Chromosomal translocations
Chromosomal abnormalities, gene fusions and copy number aberrations are 
more common in the younger patient population [28]. The ratio of structural 
variation to mutational burden decreases continuously with age, with the most 
chromosomal translocations in infants (<1 year) compared to all other ages. Within 
this young age-group, the most common fusion involves KMT2A (also known 
as MLL1), present in 38% of the infants [28]. A second age-peak is recognized 
in young to middle aged AML adults. Overall, more than 80 fusion partners of 
KMT2A are described and it is the protein partner of KMT2A that determine 
characteristics specific to age and disease. Interestingly, 50% of the infants younger 
than 1 year with ALL contain the specific MLL-AF4 fusion protein caused by the 
t(4;11)(q21,q23) translocation [29], whereas in AML, the most common MLL 
rearrangement is the MLL-AF9 that arises from a t(9;11)(p22,q23) translocation. 
In both populations, MLL leukemia confers poor prognosis and identification of 
unique proteoforms in this subtype leukemia may guide treatment stratification by 
providing targetable leads. For instance, downstream proteomic targets mediated 
by MLL-AF4 include HOX, EPHA7, MEIS, PBX and GSK-3 and these are already 
considered or investigated as therapeutic targets in the context of MLL-rearranged 
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Cancer Genome Atlas, suggesting that the number of recognized recurrent muta-
tions in AML alone is not sufficient to explain its heterogeneity. They demonstrated 
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5–15%. For older patients who are unable to receive intensive chemotherapy without 
acceptable side effects the prognosis is even more dismal, with a median survival 
of only 5–10 months [2]. Survival rates in the pediatric population, have improved 
greatly, although OS rates of 65–70% are still much lower than that for pediatric 
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contains, including an estimated of 30,000–40,000 protein-coding genes. While 
the basic dogma of biology formerly was that DNA was transcribed into messenger 
RNA, which is then translated into proteins, and that mRNA levels could be used to 
predict protein abundance, it becomes more and more clear that this is overly sim-
plistic due to our expanding knowledge of the effects of epigenetics, environmental 
influences, mRNA editing, alternative splicing and noncoding RNAs on gene 
expression. For instance, coding single-nucleotide polymorphisms and mutations 
can affect the final protein sequence and function, and based on endogenous prote-
olysis and mRNA splicing, different isoforms can be generated from the same set of 
nucleotides. Additionally, after translation of the RNA transcript, proteins undergo 
multiple modifications affecting the protein function, localization, lifespan and 
activity. Together this results in up to a million of proteoforms.
One of the first studies back in 1999, that compared a limited number of mRNA 
and proteins using Saccharomyces cerevisiae, already concluded that the correlation 
between both was only 0.36 [4, 22]. And, even with the significant improvements in 
high-throughput genomic and proteome approaches, this fundamental observation 
continues to be widely, though not universally, supported, as most studies nowadays 
still show a correlation coefficient that varies between 0.17 and 0.40. Per example, 
Mun et al. recently performed correlation analysis of mRNA and protein log2-fold 
changes between gastric cancer tumor samples and adjacent normal tissues using 
6803 genes with protein and mRNA abundances available in at least 30% (≥24) of 
the patients. Of the 6803 genes, only 34.3% showed significant (FDR < 0.01) positive 
correlation with an average correlation coefficient of 0.28 [23]. Zang et al., per-
formed an integrated proteogenomic analyses human colon and rectal cancer samples 
and while 89% of the samples showed significant positive mRNA-protein correlation 
(of which only 32% was significantly correlated), the average correlation between 
messenger RNA transcript abundance and protein abundance was only 0.23 [24].
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Aforementioned, the functional variant of a protein, the proteoform, is defined 
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and 5 years of age followed by a gradual increase in the older patients, is it suggested 
that different combinations of genetic factors (resulting in different proteoforms) 
contribute to leukemogenesis at different ages. In order to answer the question why 
genes are differentially expressed upon age, a closer look at biological processes that 
influence the final proteoform production via pre-translational modifications may 
help. Here we will discuss a few examples of how these differ between younger and 
older patients with acute leukemia.
4.1 Genetic variants
Emerging genome wide sequencing techniques identified disease and age-spe-
cific gene variants in acute leukemia. For example, Perez-Andreu et al. discovered a 
single nucleotide polymorphism (SNP), a variant of the coding region of the DNA, 
of GATA3 on 10p14 that was associated with the susceptibility to ALL in adolescents 
and young adults, and that progressively increased with age [25]. Furthermore, 
genomic variants that occur in both pediatric and adult leukemia sometimes display 
a different phenotype at the protein level. As shown by Zuurbier et al., loss of PTEN 
protein due to the production of an unstable and truncated proteoform caused by 
a frameshift mutation or genomic deletion is a frequently seen in T-cell ALL (pre-
dominantly in pediatric T-ALL). PTEN is often recognized as a tumor suppressor, 
but its behavior and relation to outcome is highly context dependent. PTEN abnor-
malities may impact NOTCH1 and, in a cohort of PTEN mutated pediatric T-ALL 
patients (with loss of PTEN protein) that lacked the NOTCH1 activating mutations, 
had significantly fewer relapses compared to patients with activated PTEN and 
NOTCH1 [26]. In contrast, another study showed that PTEN mutations without 
NOTCH1 abnormalities were associated with poor prognosis in adults [37]. Thus, 
genomic mutations within the same gene, do not always produce the same proteo-
form with the same function. Mutations can create a proteoform with a completely 
different function and can convert a protein from a tumor suppressor into a tumor 
driver [27]. Although, genome wide studies are very meaningful in detection of 
conditions specific to age and disease, but the net effect on the cell largely depends 
on the production of the final proteoform (tumor suppressor or tumor driver) and 
the pathways they act in.
4.2 Chromosomal translocations
Chromosomal abnormalities, gene fusions and copy number aberrations are 
more common in the younger patient population [28]. The ratio of structural 
variation to mutational burden decreases continuously with age, with the most 
chromosomal translocations in infants (<1 year) compared to all other ages. Within 
this young age-group, the most common fusion involves KMT2A (also known 
as MLL1), present in 38% of the infants [28]. A second age-peak is recognized 
in young to middle aged AML adults. Overall, more than 80 fusion partners of 
KMT2A are described and it is the protein partner of KMT2A that determine 
characteristics specific to age and disease. Interestingly, 50% of the infants younger 
than 1 year with ALL contain the specific MLL-AF4 fusion protein caused by the 
t(4;11)(q21,q23) translocation [29], whereas in AML, the most common MLL 
rearrangement is the MLL-AF9 that arises from a t(9;11)(p22,q23) translocation. 
In both populations, MLL leukemia confers poor prognosis and identification of 
unique proteoforms in this subtype leukemia may guide treatment stratification by 
providing targetable leads. For instance, downstream proteomic targets mediated 
by MLL-AF4 include HOX, EPHA7, MEIS, PBX and GSK-3 and these are already 
considered or investigated as therapeutic targets in the context of MLL-rearranged 
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leukemia. In addition, RAS, DOT1L, and HSP-90 also have been described as 
potential targets in MLL leukemia [30]. As those genes and their protein products 
are in particular involved in transcription regulation, we hypothesize that patients 
that expression differences in those conserved genes, likely also harbor differences 
in abundance, or proteoforms of its downstream proteins, compared to wild-type 
patients.
4.3 Non-coding microRNAs
MicroRNAs (miRNA) are small non-coding RNAs that affect the proteome 
through their binding to mRNA influencing/inhibiting the translation to proteins. 
Aberrant miRNA expression is associated with leukemogenesis [31], and multiple 
miRNAs are found to be expressed differently upon age. A study by Noren Hooten 
et al. showed downregulation of miRNA expression in peripheral blood of healthy 
individuals with advancing age. Cancer is often age-related and five out of nine 
downregulated miRNAs in this study were related to cancer pathogenesis [32]. 
Another study compared miRNA profiles between pediatric and adult patients 
with AML and again, identified significant lower miRNA expression in adults 
compared to children. In addition, they found distinct miRNA expression pat-
terns in both t(8;21) and t(15;17) translocated pediatric AML, but not in adults. 
Also, nine-fold upregulation of miR-21 was identified in the MLL-rearranged 
pediatric patients compared to others and this finding was also not reflected by the 
MLL-rearranged adult population [33]. The identification of age-specific miRNA 
specific expressing in leukemia together with the fact that miRNA will affect the 
final proteomic state, indicates that further proteomic approaches could likely 
unravel differences in proteoforms between younger and older patients within 
leukemic subtypes.
4.4 Post-translational modifications
DNA is wrapped around histone to form a compact chromatin structure and 
PTMs on histone tails, such as the addition or removal of methyl or acetyl groups 
on lysine residues, or direct DNA methylation regulate chromatin accessibility 
and initiate and maintain gene expression patterns that account for specific cell 
lineage differentiation and development [34]. Packaging of the chromatin struc-
ture changes with age and include global loss of heterochromatin resulting in a 
more open chromatin state in the elderly. Reduction of heterochromatin due to 
increased histone acetylation during aging is also well-established [35, 36], but less 
well-characterized is the role of histone methylation. Since the prevalence of AML 
increases with age, we asked ourselves if histone methylation profiles are different 
between pediatric and adult AML. We recently applied RPPA-based profiling using 
antibodies against multiple histone methylation sites which enabled us to define 
disease and age characteristic patterns of histone modification. In agreement with 
our hypothesis, a significant decline in histone methylation was seen upon age in 
both ALL and AML cases (manuscript in preparation).
As mentioned, MLL-rearrangements are specific to age and disease, and are 
frequently altered in leukemia. As MLL fusion proteins modulate the chromatin 
structure by histone tail modifications, MLL-rearranged leukemia is considered as 
epigenetic malignancy. In addition, mutations in proteins that modify the histone 
PTM process (e.g. writers, erasers and readers) are more frequently found in T-ALL 
compared to other childhood malignancies, and distinct DNA methylation patterns 
were recognized among different subtypes of ALL. Those patterns correlated with 
changed transcriptomes. Aberrant DNA methylation is associated with silencing of 
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genes that involved in lymphoid development, and contribute to leukemogenesis. 
By combining DNA methylation and transcriptome analysis, transcriptional silenc-
ing via promotor hypermethylation was recently identified in pediatric AML [28], 
and correlated with age, karyotype and outcome.
Since hypomethylating agents have been widely used to treat, in particular the 
older leukemia patients, we hypothesize that proteomics can help to identify more 
refined subgroups (maybe even from the younger population) that can be treated 
with certain treatment regimens that alter the epigenome. For instance, the discov-
ery of a specific protein or proteomic signature (either related to the epigenome or 
not) that is correlated with sensitivity to hypomethylating agents, can potentially 
act as biomarker in MLL-rearranged leukemia, to select patients that can benefit 
from those agents. In the experimental setting, therapies with hypomethylating 
agents have already showed re-expression of the hypermethylated genes along 
with restored chemosensitivity, and in relapsed ALL, increased promotor methyla-
tion was found to be related to increased chemoresistance [37]. If it is possible to 
identify a set of proteins that is specific for relapsed MLL-rearrangement AML 
and/or ALL, rapid tests (e.g. ELISA, IHC or FPPA) could be developed to quickly 
provide information about the protein abundance in relapsed patients, to identify 
those who will benefit from additional treatment, as well as, a priori, predict which 
newly diagnosed patients are most likely to relapse, and treat those with additional 
treatment to prevent relapse.
5. Oncogenic proteoforms leading to leukemia
Mutations in the DNA of the hematopoietic stem cells play a pivotal role in leu-
kemogenesis and within single genes, multiple mutations have been identified that 
results in different forms of the protein. One example involves transcription factor 
CCAAT/enhancer binding protein A (CEBPA) mutated AML patients, which is known 
to regulate growth arrest and differentiation in hematopoiesis by promoting granu-
locyte lineage differentiation in common myeloid progenitor cells, and disruption of 
normal CEBPA expression in myeloid progenitors may lead to a block in granulopoi-
esis resulting in erythropoiesis in its place [38]. As critical regulator of myeloid lineage 
development it is not surprising that CEBPA is mutated in ~10% of AML patients 
and most frequently classified as myeloblastic AML subtype M1 of M2 according 
the French-American-British (FAB) classification. CEBPA transcript translates for 
a full-length (CEBPA-p42) or shorter isoform (CEBPA-p30). CEBPA-p30 isoforms 
contain the DNA binding domain but lack the N-terminal transactivation domain. 
However, CEBPA-p30 is dominant negative by reducing transcriptional activity after 
heterodimerization with full-length CEBPA-p42. About half of CEBPA mutated AML 
patients have one allele with a N-terminal mutation and one allele with a C-terminal 
mutation. The N-terminal mutant results in translational termination of the full-
length isoform and increase truncated CEBPA-p30 expression. In contrast, C-terminal 
mutations in CEBPA-p42 are mostly characterized by in-frame basic region leucine 
zipper (bZIP) variants inhibiting normal CEBPA function by disrupting DNA binding 
and dimerization [39]. CEBPA mutated patients might be candidates for inhibition of 
the oncogenic CEBPA-p30 isoform to recover the disrupted p42/p30-ratio.
6. High-throughput proteomics methodologies
Proteomics may be the least developed and investigated “-omics” approach, it is 
likely one of the most informative for understanding of cellular behavior as it can 
Proteoforms - Concept and Applications in Medical Sciences
66
leukemia. In addition, RAS, DOT1L, and HSP-90 also have been described as 
potential targets in MLL leukemia [30]. As those genes and their protein products 
are in particular involved in transcription regulation, we hypothesize that patients 
that expression differences in those conserved genes, likely also harbor differences 
in abundance, or proteoforms of its downstream proteins, compared to wild-type 
patients.
4.3 Non-coding microRNAs
MicroRNAs (miRNA) are small non-coding RNAs that affect the proteome 
through their binding to mRNA influencing/inhibiting the translation to proteins. 
Aberrant miRNA expression is associated with leukemogenesis [31], and multiple 
miRNAs are found to be expressed differently upon age. A study by Noren Hooten 
et al. showed downregulation of miRNA expression in peripheral blood of healthy 
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genes that involved in lymphoid development, and contribute to leukemogenesis. 
By combining DNA methylation and transcriptome analysis, transcriptional silenc-
ing via promotor hypermethylation was recently identified in pediatric AML [28], 
and correlated with age, karyotype and outcome.
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older leukemia patients, we hypothesize that proteomics can help to identify more 
refined subgroups (maybe even from the younger population) that can be treated 
with certain treatment regimens that alter the epigenome. For instance, the discov-
ery of a specific protein or proteomic signature (either related to the epigenome or 
not) that is correlated with sensitivity to hypomethylating agents, can potentially 
act as biomarker in MLL-rearranged leukemia, to select patients that can benefit 
from those agents. In the experimental setting, therapies with hypomethylating 
agents have already showed re-expression of the hypermethylated genes along 
with restored chemosensitivity, and in relapsed ALL, increased promotor methyla-
tion was found to be related to increased chemoresistance [37]. If it is possible to 
identify a set of proteins that is specific for relapsed MLL-rearrangement AML 
and/or ALL, rapid tests (e.g. ELISA, IHC or FPPA) could be developed to quickly 
provide information about the protein abundance in relapsed patients, to identify 
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newly diagnosed patients are most likely to relapse, and treat those with additional 
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5. Oncogenic proteoforms leading to leukemia
Mutations in the DNA of the hematopoietic stem cells play a pivotal role in leu-
kemogenesis and within single genes, multiple mutations have been identified that 
results in different forms of the protein. One example involves transcription factor 
CCAAT/enhancer binding protein A (CEBPA) mutated AML patients, which is known 
to regulate growth arrest and differentiation in hematopoiesis by promoting granu-
locyte lineage differentiation in common myeloid progenitor cells, and disruption of 
normal CEBPA expression in myeloid progenitors may lead to a block in granulopoi-
esis resulting in erythropoiesis in its place [38]. As critical regulator of myeloid lineage 
development it is not surprising that CEBPA is mutated in ~10% of AML patients 
and most frequently classified as myeloblastic AML subtype M1 of M2 according 
the French-American-British (FAB) classification. CEBPA transcript translates for 
a full-length (CEBPA-p42) or shorter isoform (CEBPA-p30). CEBPA-p30 isoforms 
contain the DNA binding domain but lack the N-terminal transactivation domain. 
However, CEBPA-p30 is dominant negative by reducing transcriptional activity after 
heterodimerization with full-length CEBPA-p42. About half of CEBPA mutated AML 
patients have one allele with a N-terminal mutation and one allele with a C-terminal 
mutation. The N-terminal mutant results in translational termination of the full-
length isoform and increase truncated CEBPA-p30 expression. In contrast, C-terminal 
mutations in CEBPA-p42 are mostly characterized by in-frame basic region leucine 
zipper (bZIP) variants inhibiting normal CEBPA function by disrupting DNA binding 
and dimerization [39]. CEBPA mutated patients might be candidates for inhibition of 
the oncogenic CEBPA-p30 isoform to recover the disrupted p42/p30-ratio.
6. High-throughput proteomics methodologies
Proteomics may be the least developed and investigated “-omics” approach, it is 
likely one of the most informative for understanding of cellular behavior as it can 
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provide useful information about both protein abundance and activity, as regulated 
by the PTM, the protein-protein and protein-DNA interactions. Nowadays, two of the 
most commonly used high-throughput techniques to study the proteome in leukemia 
are mass-spectrometry (MS)-based techniques and antibody-based techniques.
6.1 MS-based
MS is a high-throughput technique uses the formation of ions (charged frag-
ments) from the protein analyte to distinguish between proteoforms. Those ions 
can be sorted and measured using electrical and/or magnetic fields based on their 
mass-to-charge ratio (m/z), and identification of the protein follows based on the 
abundance of those m/z-fragments [40]. Globally, proteins can be ionized with two 
distinct methods: matrix assisted laser desorption/ionization (MALDI) and elec-
trospray ionization (ESI). In MALDI the protein sample is mixed with an energy 
absorbing matrix. Irradiation of this matrix causes vaporization of the matrix 
together with the sample, resulting in the formation of ions [41]. ESI creates ions 
using electrospray to dissolve the protein lysate, by applying high-voltage to the 
dissolvent to create an aerosol of small charged fragments. When a protein sample 
is highly complex, samples may require separation prior to MS analysis using 1D 
or 2D gel electrophoresis, high-pressure liquid chromatography (LC-MS), or gas 
chromatography (GC-MS) to maximize the sensitivity. Because proteoforms are 
derived from a single gene, they often contain homologous sequence regions, and 
because of the digestion step, information about the relationship between amino 
acid sequence and the PTM often lacks, this significantly complicates the process of 
identifying proteoforms. Several overviews have been published that discuss recent 
technological developments of MS to enable analysis distinct proteoforms [42–44].
6.2 Antibody-based
Another high-throughput approach is the protein microarray (PMA), of which 
two different types exist: forward phase protein arrays (FPPA) and reverse phase 
protein arrays (RPPA). Given that antibodies can be raised to specifically recognize 
sequence variations or PTM, they enable measurement of selected proteoforms. 
In FPPA, protein antibodies are immobilized on an array in known positions, and 
samples are then printed on the array. If a particular proteoform is present in the 
sample, the proteoform binds to the antibody and after exposure to a secondary 
antibody, the abundance can be measured. Each slide is incubated with a single 
protein sample, but multiple proteins can be measured simultaneously depending 
on the number of antibodies printed on the slide.
The “reverse” version of the FPPA is the RPPA methodology. In RPPA, samples 
are first printed on the array, and subsequently each slide is stained with a single 
protein antibody, followed by a secondary antibody to amplify the signal. The 
downsides of RPPA are that all samples must be printed at the same time to avoid 
methodological barriers due to printing irregularities between batches, and that 
RPPA can only be used to detect proteins for which a strictly validated antibody is 
available. As there is no separation of the proteins according to molecular weight, 
it is crucial that antibodies are proven to be highly specific, selective and reproduc-
ible. Plus, RPPA is biased to proteins and isoforms for which a strictly validated 
antibody is available. On the other hand, RPPA requires only a small number of 
cells (approximately 3 × 105 cells to test 400 different antibodies), making it highly 
suitable for retrospective clinical applications. As it in addition analyzes all samples 
at once, it allows a direct comparison of protein abundance across samples.
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7. Proteomics in acute leukemia
7.1  Disease-specific proteoform landscape of acute myeloid leukemia and acute 
lymphoid leukemia
Acute leukemia is a heterogeneous group of diseases both in terms of biology 
and prognosis. Classification into those arising from the myeloid or the lymphoid 
lineage is based on cytomorphology and cytochemistry, with further differentiation 
into specific subgroups based on morphology, immunophenotyping, cytogenetics, 
and molecular genetics of the acute leukemia cells. However, present classification 
systems are not adequate to differentiate between all subtypes and do not always 
accurately predict the clinical outcome. Whether changes in the leukemic cells that 
cause those differences are due to developmental, genetic, or environmental effects, 
they all are ultimately mediated by changes in protein abundance or modification. 
Therefore, we hypothesize that systematic comparative or differential proteomics 
can discover changes in the presence and quantity of individual proteoforms that 
underlie these cellular changes, and can add to current diagnostics, prognostics and 
therapeutics.
Assessment of the “diseased”-proteome compared to the proteome of the 
“normal/healthy” cells (e.g. CD34+, CD38+CD34+, CD38−CD34+; a discussion 
about the optimal normal comparator is discussed elsewhere [45]) can identify 
proteins that are aberrantly expressed or activated compared to normal, as well as 
can identify different forms of the same protein that differ between the diseased 
cell and the healthy comparator. This enables recognition of pathways utilization of 
cells present within a certain set of patients or related to a specific clinical feature. 
In addition, proteins or sets of proteins that are differentially expressed, may aid for 
confirmatory diagnostic purposes and early disease detection.
Furthermore, detailed proteomic profiling can help identifying differences 
between subgroups of diseases, including ALL and AML, and also between 
subgroups within one of both. It may be important (informative) to know how 
these two diseases are similar as well as how they differ. As ALL and AML are both 
dominated by immature malignant hematopoietic cells, they can serve as lineage-
independent control for each other. Defining which proteins display similar expres-
sion in ALL and AML, but which are different compared to the “normal” healthy 
control, or to more mature cells, are likely to be related to a block in differentiation, 
whereas other proteins patterns that are similar in both, could be related to the 
hallmark of uncontrolled proliferation, resistance to cell death, or other shared 
deregulations.
As example, Cui et al. performed proteomic analysis using 2D-MS for 61 bone 
marrow biopsies from patients diagnosed with French-American-British (FAB) 
M1-M5 AML or ALL [46, 47]. Comparative analysis, identified 27 proteins with 
lineage-specific expression. Among them, myeloperoxidase was already known to 
be highly expressed in AML compared to ALL, but they also recognized heat shock 
factor binding protein 1 (HSBP1) as being high in ALL. In addition, they found 
proteins that were higher expressed in M2 and M3 AML compared to M1, and 23 
proteins that were differentially expressed between granulocytic lineage (M1, M2, 
M3) AML, and AML derived from the monocytic lineage (M5). To prove clinical 
usefulness, Cui et al. also applied proteomic analysis to an AML-M3 bone marrow 
(which was classified based on morphology by the presence of atypical granules) 
from a patient who did not respond to the standard differentiation-inducing 
therapy with all-trans retinoic acid or As2O3. Their analysis showed that this sample 
exhibited a “protein expression profile” specific to M1, and not to M3, and after 
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changing this treatment to chemotherapy, the patient gained complete remis-
sion within 3 weeks. Xu et al. performed proteomic profiling of the bone marrow 
samples from patients with different subtypes of acute leukemia (APL, AML, ALL) 
and healthy volunteers by SELDI-TOF-MS. Based on 109 protein signatures, they 
constructed a proteomic-based classification model capable of replicating the mor-
phological and differentiation-based classification scheme of the well-established 
FAB system. Their results suggested that this mode could potentially serve as new 
diagnostic approach [48].
In our own group, we performed proteomic profiling using RPPA for 265 
patients, in which we were able to separate 3 clusters of proteins that tended to track 
similarly within a FAB class from a subset of 24 differentially abundant proteins 
and PTMs; myeloid subtypes (M0–M2), the monocytic subtypes (M4–M5), eryth-
roleukemia and megakaryocytic leukemia [49]. Foss et al. studied proteomics from 
4 AML patients and 5 ALL patients using LC-MS/MS in blasts, as well as in CD34+ 
cells from 6 healthy donors and mononuclear cells from 2 healthy donors to cor-
rect for mononuclear cell contamination. Blinded unsupervised clustering enabled 
grouping with each cell type forming a discrete cluster, suggesting that proteomics 
can indeed, at least in some cases, robustly distinguish known classes of leukemia.
Recently, another study by our group analyzed pediatric AML (n = 95) and 
pediatric ALL (n = 73) on RPPA for antibodies against 149 different total proteins in 
addition to 45 antibodies recognizing different PTMs (e.g. phosphorylation, histone 
modification and cleavage) [50]. We felt that traditional hierarchical clustering was 
suboptimal as it weighs all proteins equally, in all situations across the dataset, and 
is agnostic to all known functional relationships between proteins, ignoring known 
interactions. Hence, we developed a novel computational method that accounts for 
known functional interactions which we call the “MetaGalaxy” approach [50–52]. 
This methodology starts with the allocation of proteins into groups of proteins with 
a related function based on existing knowledge or strong association within this 
dataset (“Protein Functional Group” (PFG), n = 31). For each PFG, a clustering 
algorithm enabled recognition of an optimal number of protein clusters; a subset of 
cases with similar (correlated) expression of core PFG components.
In order to know how the activity between the different PFG relate to each other 
within pediatric ALL and AML, we next hypothesized that there would be recurrent 
patterns of interaction between the various PFG clusters that would form a finite set 
of “protein expression signatures” that are shared by different subsets of patients. 
Therefore, patients were clustered based on their protein cluster membership using 
a binary matrix system. Correlation between protein clusters from various PFG was 
defined as a “Protein Constellation”. We were able to identify subgroups of patients 
(signatures) that expressed similar combinations of protein constellations.
With this segmented approach a substantial amount of structure was observed 
across the data set (Figure 1), with an optimal number of 12 constellations and 
12 signatures. Notably, signatures were strongly associated the leukemia-lineage. 
Signature 1 and 2 were specific to T-ALL (Figure 1, annotated in pink), whereas 
signatures 3, 4 and 5 were dominant to B-ALL and signature 7–12 to AML. Only 
signature 6 was a mixture of both B-ALL and AML patients. This clear distinction 
could also be discerned by the constellations. Protein constellation 1–4 were all 
specific to ALL, with constellation 1 (Figure 1, magenta box) only being found in 
B-ALL, 4 exclusively to T-ALL (Figure 1, yellow box), and 2 and 3 being present in 
both B- and T-ALL. On the other hand, constellation 7 and 8 were strongly associ-
ated with AML (Figure 1, blue box) and constellation 5 and 6 were found in both 
ALL and AML.
We also identified proteins that were universally changed in the same direction 
in at least 6 of the 8 signatures. Interestingly, GATA1 and STAT1 were universally 
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lower expressed in both pediatric AML and adult AML patients, whereas and 
phosphorylated RB1-pSer807_811, a phosphorylation event that deactivates the RB1 
protein, showed universally opposite expression in children and adults, being 
predominantly unphosphorylated (active) in pediatric patients and highly phos-
phorylated (inactive) in adults. For pediatric AML and ALL samples, comparable 
expressions were seen for the higher expressed universals CASP7 cleaved at domain 
198 and phosphorylated CDKN1B-pSer10, and the lower expressed JUN-pSer73 and 
GATA1.
Unpublished data from 205 adult AML and 166 adult ALL patients identified 
the existence of 11 protein signatures, of which 5 were AML dominant (93–100%), 
4 were T-ALL dominant (79–100%) and 2 signatures contained a mixture of AML, 
B-ALL, T-ALL samples (50 and 68% AML). Three out of the 12 constellations were 
predominantly associated with AML, 4 were associated with ALL, 2 were associated 
with a mixture of ALL and AML cases, and 3 signatures were not strongly associ-
ated with any particular signature. This study used a total of 230 antibodies, includ-
ing antibodies against 169 different proteins along with 52 antibodies targeting.
phosphorylation sites, 6 targeting Caspase and Parp cleavage forms and 3 
targeting histone methylation sites. A third study (manuscript in preparation) 
from 500 pediatric AML, 68 adult T-ALL and 290 pediatric T-ALL patients, again 
showed similar results, with T-ALL and AML dominant signatures (81.5–100%), 
and only 1 out of the 15 signatures that had both T-ALL and AML (39% T-ALL and 
61% AML). This clearly suggests that proteomics can be used to distinguish ALL 
from AML, and that although ALL and AML are very different in terms of overall 
proteomics, they share “protein expression signatures”, which suggests that there 
Figure 1. 
“MetaGalaxy” analysis for pediatric ALL and AML. Annotations shows clear separation in protein patterns 
for T-ALL (magenta; signature 1 and 2), B-ALL (yellow; signature 3, 4, and 5), and AML (blue; signature 
7, 8, 9, 10, 11, and 12). Constellations 1 (horizontally, magenta box) is associated with T-ALL, constellation 
4 (horizontally, yellow box) with B-ALL and constellation 7 and 8 with AML (horizontally, blue box). This 
figure was adapted from Hoff et al. Molecular Cancer Research 2018 [50].
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ated with any particular signature. This study used a total of 230 antibodies, includ-
ing antibodies against 169 different proteins along with 52 antibodies targeting.
phosphorylation sites, 6 targeting Caspase and Parp cleavage forms and 3 
targeting histone methylation sites. A third study (manuscript in preparation) 
from 500 pediatric AML, 68 adult T-ALL and 290 pediatric T-ALL patients, again 
showed similar results, with T-ALL and AML dominant signatures (81.5–100%), 
and only 1 out of the 15 signatures that had both T-ALL and AML (39% T-ALL and 
61% AML). This clearly suggests that proteomics can be used to distinguish ALL 
from AML, and that although ALL and AML are very different in terms of overall 
proteomics, they share “protein expression signatures”, which suggests that there 
Figure 1. 
“MetaGalaxy” analysis for pediatric ALL and AML. Annotations shows clear separation in protein patterns 
for T-ALL (magenta; signature 1 and 2), B-ALL (yellow; signature 3, 4, and 5), and AML (blue; signature 
7, 8, 9, 10, 11, and 12). Constellations 1 (horizontally, magenta box) is associated with T-ALL, constellation 
4 (horizontally, yellow box) with B-ALL and constellation 7 and 8 with AML (horizontally, blue box). This 
figure was adapted from Hoff et al. Molecular Cancer Research 2018 [50].
Proteoforms - Concept and Applications in Medical Sciences
72
are shared patterns of deregulation within some pathways. However, as all studies 
used a mixture of both total and PTM-proteins, it would be interesting to assess 
how expression and classification differs across diseases using a panel with a larger 
number of PTM, or a panel limited to PTM only, given that PTM often provide 
information about the activity or biological function of the protein.
7.2 Global proteomic landscape of pediatric and adult T-ALL
When we assessed the global proteomic landscape in pediatric and adult T-ALL, 
using the “MetaGalaxy” approach, we found 10 signatures based on 11 constella-
tions (manuscript in preparation). Overall, signatures were not associated with age 
(i.e. pediatric vs. adult), with the exception of one signature. This signature was 
strongly associated with 2 constellations, which were only present in this particular 
signature. This suggests that pediatric T-ALL and adult T-ALL are more similar than 
ALL and AML, but that despite mostly overlapping signatures and constellations, 
there is an expression pattern specific to children. As this is similar to what we see in 
the genetics, were most recurrent aberrations are seen in both children and adults, 
but with different frequencies of occurring, correlation with genetic features would 
be interesting.
7.3 Assessing dynamic change upon treatment exposure
Children have a significant better prognosis and ALL responds better to treat-
ment than AML. In addition to extracting information about differences in baseline 
protein abundance between those groups of patients, another consideration is to 
look at the dynamic response of the cells to stress, such as chemotherapy, or apop-
totic inducers, to see whether changes in protein abundance patterns can provide 
a marker or whether a cell is responsive or resistant, and whether this is different 
between patients. Looking at post-treatment abundance and presence of proteo-
forms may provide insights into biological effects of drugs and mechanisms of drug 
resistance. This can either be done from static expression levels post-treatment at 
a given time point, or from the dynamic change in expression during treatment 
(i.e. expression post-treatment minus expression pre-treatment). Particularly, in 
leukemia, were blood can easily be drawn from the patient without performing any 
additional invasive procedures, expression can be measured at several time points 
during treatment.
Although this will not provide a priori information about which patients 
will respond to therapy or which patient needs which chemotherapy, it can give 
information about the response to treatment during early stages and so, aid in the 
decision of a more intensive treatment strategy should be achieved, or whether 
additional combinational treatment would be beneficial. For instance, if it is known 
that a particular protein pathway is utilized be the cell in order to circumvent cell 
death, in theory, this pathway can be targeted. Also, by comparing response to 
treatment on protein abundance or activity between ALL and AML, or children and 
adults, this can provide important information about why some patients respond 
while others do not.
While, theoretically, this approach would be promising, in reality this it much 
more complicated. First, of all, the time point of measuring the expression would be 
crucial. Assessment of the dynamic change too early, in cells that are not yet fatally 
hit by the chemotherapy or are in the process of dying, would suggest that the che-
motherapy does not work, or has no effect on protein level, whereas measuring too 
late would measure the expression in cells that already died. Moreover, despite the 
ability of chemotherapy to kill the vast majority of leukemic cells, the rare leukemic 
73
Proteoforms in Acute Leukemia: Evaluation of Age- and Disease-Specific Proteoform Patterns
DOI: http://dx.doi.org/10.5772/intechopen.90329
stem cell that survives the chemotherapy, and that is responsible for the outgrowth 
of the leukemia cells which is manifested as relapse or primary resistant disease, 
is the cell from which we can potentially gather the most information. Proteomic 
analysis of these resistant cells, rather than taking the average of all, might be more 
informative than the analysis of the bulk leukemia population. Especially, knowing 
how those cells respond to chemotherapy (in comparison to other), would then be 
likely to raise new biological questions about why different cells behave differently, 
and why, or how, cells are able to circumvent chemotherapy, and what can be done 
to treat those cells. However, without a current means to a priori identify those few 
cells, isolation of (enough of) those cells remain a real challenge. So, if we want to 
know what is going in, pre- and post-treatment, as means to identify who those are, 
is required.
8. Conclusions
Despite significant improvement in treatment regimes, outcomes of both pediat-
ric and adult patients with acute leukemia remain unsatisfactory. When a leukemia 
patient enters the clinic, particularly cytogenetics and mutation analysis are the 
methods of choice to perform risk stratification. And after induction therapy, 
choice of consolidation therapy is mainly based on the present chromosomal 
alternations and driver mutation(s). Emerging research in the field shows that 
prognosis is largely context-dependent and that acute leukemia are molecularly 
diverse diseases with similar phenotypes. Many years of exploration the molecular 
diversity in leukemia taught us that the combined influences of genetics, epigenetic 
remodeling, the microenvironment and PTM of leukemic blasts determine its cell 
fate. Since the net effect of these combined influences is predominantly displaced 
on the abundance and activity of the proteoforms, as well or their affected signaling 
pathways, we argue that characterization of differentially abundant proteoforms 
and recognition of proteomic patterns within and between (subgroups of) acute 
leukemia may facilitate and improve risk stratification as well as could provide 
therapeutic leads that may contribute to treatment personalization. However, while 
much is known about cytogenetics in AML and ALL, little is known about the 
proteomics of these cells.
While distinct proteoform patterns within and between different leukemic sub-
types are only beginning to be recognized, age-specific proteome characterizations 
are far more limited. Bone marrow aspiration is a relative painful procedure and 
healthy donors, such as patient relatives or medical students who donate bone mar-
row that could function as internal control against AML blasts are scarce in many 
studies. The control group therefore often does not represent the median age of 
the patient cohort and leukemic-specific findings cannot be directly compared to a 
matched age group. Many studies focusing on leukemia therefore avoid controls and 
perform internal disease comparisons. Age-related analysis is then only applicable 
when a wide age distribution across the cohort is present, but this is often not the 
case as most research focuses on either pediatric or adult leukemia, instead of both.
More research is needed to identify single proteins and sets of proteins that 
are associated with disease and age specific subgroups. As far as we know, we are 
the first to analyze protein abundance and their PTM between AML and ALL 
across all ages, using antibody-based proteomics. Almost all studies look at AML 
or ALL and if they look at both, they mainly focus on the differences rather than 
the similarities. However, ALL and AML share the same pathophysiology in terms 
of the occurrence of a differentiation block that gives rise to uncontrolled clonal 
proliferations of immature hematopoietic progenitor cells in the bone marrow. 
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cells, isolation of (enough of) those cells remain a real challenge. So, if we want to 
know what is going in, pre- and post-treatment, as means to identify who those are, 
is required.
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ric and adult patients with acute leukemia remain unsatisfactory. When a leukemia 
patient enters the clinic, particularly cytogenetics and mutation analysis are the 
methods of choice to perform risk stratification. And after induction therapy, 
choice of consolidation therapy is mainly based on the present chromosomal 
alternations and driver mutation(s). Emerging research in the field shows that 
prognosis is largely context-dependent and that acute leukemia are molecularly 
diverse diseases with similar phenotypes. Many years of exploration the molecular 
diversity in leukemia taught us that the combined influences of genetics, epigenetic 
remodeling, the microenvironment and PTM of leukemic blasts determine its cell 
fate. Since the net effect of these combined influences is predominantly displaced 
on the abundance and activity of the proteoforms, as well or their affected signaling 
pathways, we argue that characterization of differentially abundant proteoforms 
and recognition of proteomic patterns within and between (subgroups of) acute 
leukemia may facilitate and improve risk stratification as well as could provide 
therapeutic leads that may contribute to treatment personalization. However, while 
much is known about cytogenetics in AML and ALL, little is known about the 
proteomics of these cells.
While distinct proteoform patterns within and between different leukemic sub-
types are only beginning to be recognized, age-specific proteome characterizations 
are far more limited. Bone marrow aspiration is a relative painful procedure and 
healthy donors, such as patient relatives or medical students who donate bone mar-
row that could function as internal control against AML blasts are scarce in many 
studies. The control group therefore often does not represent the median age of 
the patient cohort and leukemic-specific findings cannot be directly compared to a 
matched age group. Many studies focusing on leukemia therefore avoid controls and 
perform internal disease comparisons. Age-related analysis is then only applicable 
when a wide age distribution across the cohort is present, but this is often not the 
case as most research focuses on either pediatric or adult leukemia, instead of both.
More research is needed to identify single proteins and sets of proteins that 
are associated with disease and age specific subgroups. As far as we know, we are 
the first to analyze protein abundance and their PTM between AML and ALL 
across all ages, using antibody-based proteomics. Almost all studies look at AML 
or ALL and if they look at both, they mainly focus on the differences rather than 
the similarities. However, ALL and AML share the same pathophysiology in terms 
of the occurrence of a differentiation block that gives rise to uncontrolled clonal 
proliferations of immature hematopoietic progenitor cells in the bone marrow. 
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Defining which proteoforms have similar expression in ALL and AML, but differ-
ent expression compared to the “normal” healthy control or to more mature cells 
are likely to be related to a block in differentiation. Other similar protein patterns 
could be related to the hallmark of an uncontrolled proliferation or resistance to 
apoptosis. Identification of differences in proteomic profiles between ALL and 
AML can additionally lead to lineage-specific proteomic signatures which may help 
to distinguish (subgroups) of the diseases.
Recognition of similar and dissimilar proteomic patterns among acute leukemia 
should also be analyzed in relation to responses to therapy. Treatment that is used 
in one group that was highly sensitive to it can be tested in other groups based on 
similar proteomic patterns. Cytogenetic and mutational information provides prog-
nostic information, but so far lacks the a priori information to predict treatment 
outcomes. Rational selection of targeted therapies based on the functional activity 
state of the cell, as determined by the proteome, is more likely to sensitize patients 
for certain treatment regimens compared to random selection.
Conflict of interest
The authors declare no conflict of interest.
Author details
Fieke W. Hoff1*†, Anneke D. van Dijk1† and Steven M. Kornblau2*
1 Department of Pediatric Oncology/Hematology, Beatrix Children’s Hospital, 
University Medical Center Groningen, University of Groningen, Groningen,  
The Netherlands
2 Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 
Houston, TX, USA
*Address all correspondence to: f.w.hoff@umcg.nl and skornblau@mdanderson.org
† These authors contributed equally to the work.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
75
Proteoforms in Acute Leukemia: Evaluation of Age- and Disease-Specific Proteoform Patterns
DOI: http://dx.doi.org/10.5772/intechopen.90329
References
[1] Inaba H, Greaves M, Mullighan CG. 
Acute lymphoblastic leukaemia. The 
Lancet. 2013;381(9881):1943-1955
[2] Döhner H, Weisdorf DJ, 
Bloomfield CD. Acute myeloid leukemia. 
The New England Journal of Medicine. 
2015;373(12):1136-1152
[3] Genshaft AS, Li S, Gallant CJ, 
Darmanis S, Prakadan SM, Ziegler CGK, 
et al. Multiplexed, targeted profiling 
of single-cell proteomes and 
transcriptomes in a single reaction. 
Genome Biology. 2016;17(1):188
[4] Payne SH. The utility of protein 
and mRNA correlation. Trends in 
Biochemical Sciences. 2015;40(1):1-3
[5] Vogel C, Marcotte EM. Insights into 
the regulation of protein abundance 
from proteomic and transcriptomic 
analyses. Nature Reviews. Genetics. 
2012;13(4):227-232
[6] Katz AJ, Chia VM, Schoonen WM, 
Kelsh MA. Acute lymphoblastic 
leukemia: An assessment of 
international incidence, survival, 
and disease burden. Cancer Causes & 
Control: CCC. 2015;26(11):1627-1642
[7] Iacobucci I, Mullighan CG. Genetic 
basis of acute lymphoblastic leukemia. 
Journal of Clinical Oncology. 
2017;35(9):975-983
[8] Boissel N, Baruchel A. Acute 
lymphoblastic leukemia in adolescent 
and young adults: Treat as adults or as 
children? Blood. 2018;132(4):351-361
[9] Van Vlierberghe P, Ferrando A. 
The molecular basis of T cell acute 
lymphoblastic leukemia. Journal 
of Clinical Investigation. 2012; 
122(10):3398
[10] Bhojwani D, Yang JJ, Pui CH.  
Biology of childhood acute 
lymphoblastic leukemia. Pediatric 
Clinics of North America. 2015;62(1): 
47-60
[11] Pieters R, Schrappe M, De 
Lorenzo P, Hann I, De Rossi G, 
Felice M, et al. A treatment protocol 
for infants younger than 1 year with 
acute lymphoblastic leukaemia 
(Interfant-99): An observational study 
and a multicentre randomised trial. The 
Lancet. 2007;370(9583):240-250
[12] Pui C, Gaynon PS, Boyett JM, 
Chessells JM, Baruchel A, 
Kamps W, et al. Outcome of treatment 
in childhood acute lymphoblastic 
leukaemia with rearrangements of the 
11q23 chromosomal region. The Lancet. 
2002;359(9321):1909-1915
[13] Hunger SP, Loh ML, Whitlock JA, 
Winick NJ, Carroll WL, Devidas M, 
et al. Children's Oncology Group's 
2013 blueprint for research: Acute 
lymphoblastic leukemia. Pediatric Blood 
& Cancer. 2013;60(6):957-963
[14] Rubnitz JE, Lensing S, Zhou Y, 
Sandlund JT, Razzouk BI, Ribeiro RC, 
et al. Death during induction therapy 
and first remission of acute leukemia 
in childhood: The St. Jude experience. 
Cancer. 2004;101(7):1677-1684
[15] Siegel RL, Miller KD, Jemal A. 
Cancer statistics, 2017. CA: A Cancer 
Journal for Clinicians. 2017;67(1):7-30
[16] Arber DA, Orazi A, Hasserjian R, 
Thiele J, Borowitz MJ, Le Beau MM, 
et al. The 2016 revision to the World 
Health Organization classification of 
myeloid neoplasms and acute leukemia. 
Blood. 2016;127(20):2391-2405
[17] Bullinger L, Döhner K, Döhner H. 
Genomics of acute myeloid leukemia 
diagnosis and pathways. Journal of 
Clinical Oncology. 2017;35(9):934-946
Proteoforms - Concept and Applications in Medical Sciences
74
Defining which proteoforms have similar expression in ALL and AML, but differ-
ent expression compared to the “normal” healthy control or to more mature cells 
are likely to be related to a block in differentiation. Other similar protein patterns 
could be related to the hallmark of an uncontrolled proliferation or resistance to 
apoptosis. Identification of differences in proteomic profiles between ALL and 
AML can additionally lead to lineage-specific proteomic signatures which may help 
to distinguish (subgroups) of the diseases.
Recognition of similar and dissimilar proteomic patterns among acute leukemia 
should also be analyzed in relation to responses to therapy. Treatment that is used 
in one group that was highly sensitive to it can be tested in other groups based on 
similar proteomic patterns. Cytogenetic and mutational information provides prog-
nostic information, but so far lacks the a priori information to predict treatment 
outcomes. Rational selection of targeted therapies based on the functional activity 
state of the cell, as determined by the proteome, is more likely to sensitize patients 
for certain treatment regimens compared to random selection.
Conflict of interest
The authors declare no conflict of interest.
Author details
Fieke W. Hoff1*†, Anneke D. van Dijk1† and Steven M. Kornblau2*
1 Department of Pediatric Oncology/Hematology, Beatrix Children’s Hospital, 
University Medical Center Groningen, University of Groningen, Groningen,  
The Netherlands
2 Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 
Houston, TX, USA
*Address all correspondence to: f.w.hoff@umcg.nl and skornblau@mdanderson.org
† These authors contributed equally to the work.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
75
Proteoforms in Acute Leukemia: Evaluation of Age- and Disease-Specific Proteoform Patterns
DOI: http://dx.doi.org/10.5772/intechopen.90329
References
[1] Inaba H, Greaves M, Mullighan CG. 
Acute lymphoblastic leukaemia. The 
Lancet. 2013;381(9881):1943-1955
[2] Döhner H, Weisdorf DJ, 
Bloomfield CD. Acute myeloid leukemia. 
The New England Journal of Medicine. 
2015;373(12):1136-1152
[3] Genshaft AS, Li S, Gallant CJ, 
Darmanis S, Prakadan SM, Ziegler CGK, 
et al. Multiplexed, targeted profiling 
of single-cell proteomes and 
transcriptomes in a single reaction. 
Genome Biology. 2016;17(1):188
[4] Payne SH. The utility of protein 
and mRNA correlation. Trends in 
Biochemical Sciences. 2015;40(1):1-3
[5] Vogel C, Marcotte EM. Insights into 
the regulation of protein abundance 
from proteomic and transcriptomic 
analyses. Nature Reviews. Genetics. 
2012;13(4):227-232
[6] Katz AJ, Chia VM, Schoonen WM, 
Kelsh MA. Acute lymphoblastic 
leukemia: An assessment of 
international incidence, survival, 
and disease burden. Cancer Causes & 
Control: CCC. 2015;26(11):1627-1642
[7] Iacobucci I, Mullighan CG. Genetic 
basis of acute lymphoblastic leukemia. 
Journal of Clinical Oncology. 
2017;35(9):975-983
[8] Boissel N, Baruchel A. Acute 
lymphoblastic leukemia in adolescent 
and young adults: Treat as adults or as 
children? Blood. 2018;132(4):351-361
[9] Van Vlierberghe P, Ferrando A. 
The molecular basis of T cell acute 
lymphoblastic leukemia. Journal 
of Clinical Investigation. 2012; 
122(10):3398
[10] Bhojwani D, Yang JJ, Pui CH.  
Biology of childhood acute 
lymphoblastic leukemia. Pediatric 
Clinics of North America. 2015;62(1): 
47-60
[11] Pieters R, Schrappe M, De 
Lorenzo P, Hann I, De Rossi G, 
Felice M, et al. A treatment protocol 
for infants younger than 1 year with 
acute lymphoblastic leukaemia 
(Interfant-99): An observational study 
and a multicentre randomised trial. The 
Lancet. 2007;370(9583):240-250
[12] Pui C, Gaynon PS, Boyett JM, 
Chessells JM, Baruchel A, 
Kamps W, et al. Outcome of treatment 
in childhood acute lymphoblastic 
leukaemia with rearrangements of the 
11q23 chromosomal region. The Lancet. 
2002;359(9321):1909-1915
[13] Hunger SP, Loh ML, Whitlock JA, 
Winick NJ, Carroll WL, Devidas M, 
et al. Children's Oncology Group's 
2013 blueprint for research: Acute 
lymphoblastic leukemia. Pediatric Blood 
& Cancer. 2013;60(6):957-963
[14] Rubnitz JE, Lensing S, Zhou Y, 
Sandlund JT, Razzouk BI, Ribeiro RC, 
et al. Death during induction therapy 
and first remission of acute leukemia 
in childhood: The St. Jude experience. 
Cancer. 2004;101(7):1677-1684
[15] Siegel RL, Miller KD, Jemal A. 
Cancer statistics, 2017. CA: A Cancer 
Journal for Clinicians. 2017;67(1):7-30
[16] Arber DA, Orazi A, Hasserjian R, 
Thiele J, Borowitz MJ, Le Beau MM, 
et al. The 2016 revision to the World 
Health Organization classification of 
myeloid neoplasms and acute leukemia. 
Blood. 2016;127(20):2391-2405
[17] Bullinger L, Döhner K, Döhner H. 
Genomics of acute myeloid leukemia 
diagnosis and pathways. Journal of 
Clinical Oncology. 2017;35(9):934-946
Proteoforms - Concept and Applications in Medical Sciences
76
[18] Bolouri H, Farrar JE, Triche TJ, 
Ries RE, Lim EL, Alonzo TA, et al. The 
molecular landscape of pediatric acute 
myeloid leukemia reveals recurrent 
structural alterations and age-specific 
mutational interactions. Nature 
Medicine. 2018;24(1):103-112
[19] Ley TJ, Miller C, Ding L, 
Raphael BJ, Mungall AJ, 
Robertson AG, et al. Genomic and 
epigenomic landscapes of adult de 
novo acute myeloid leukemia. The 
New England Journal of Medicine. 
2013;368(22):2059-2074
[20] Papaemmanuil E, Gerstung M, 
Bullinger L, Gaidzik VI, Paschka P, 
Roberts ND, et al. Genomic 
classification and prognosis in 
acute myeloid leukemia. The New 
England Journal of Medicine. 
2016;374(23):2209-2221
[21] Gamis AS, Alonzo TA, 
Perentesis JP, Meshinchi S. Children's 
oncology Group's 2013 blueprint 
for research: Acute myeloid 
leukemia. Pediatric Blood & Cancer. 
2013;60(6):964-971
[22] Gygi SP, Rochon Y, Franza BR, 
Aebersold R. Correlation between 
protein and mRNA abundance in 
yeast. Molecular and Cellular Biology. 
1999;19(3):1720-1730
[23] Mun D, Bhin J, Kim J, Kim S, 
Kim HK, Kim DH, et al. Proteogenomic 
characterization of human early-
onset gastric cancer. Cancer Cell. 
2019;35(1):124.e10
[24] Zhang B, Wang J, Wang X, 
Zhu J, Liu Q , Shi Z, et al. Proteogenomic 
characterization of human 
colon and rectal cancer. Nature. 
2014;513(7518):382-387
[25] Perez-Andreu V, Roberts KG, Xu H, 
Smith C, Zhang H, Yang W, et al. A 
genome-wide association study of 
susceptibility to acute lymphoblastic 
leukemia in adolescents and young 
adults. Blood. 2015;125(4):680-686
[26] Zuurbier L, Petricoin EF, 
Vuerhard MJ, Calvert V, Kooi C, 
Buijs-Gladdines JGCAM, et al. The 
significance of PTEN and AKT 
aberrations in pediatric T-cell 
acute lymphoblastic leukemia. 
Haematologica. 2012;97(9):1405-1413
[27] Trinquand A, Tanguy-Schmidt A, 
Ben Abdelali R, Lambert J, Beldjord K, 
Lengliné E, et al. Toward a NOTCH1/
FBXW7/RAS/PTEN–based 
oncogenetic risk classification of 
adult T-cell acute lymphoblastic 
leukemia: A group for research in 
adult acute lymphoblastic leukemia 
study. Journal of Clinical Oncology. 
2013;31(34):4333-4342
[28] Bolouri H, Farrar JE, Triche T, 
Capone S, Ramsingh G, Ries RE, et al. 
The molecular landscape of pediatric 
acute myeloid leukemia reveals 
recurrent structural alterations and age-
specific mutational interactions. Nature 
Medicine. 2019;24(1):103-112
[29] Winters AC, Bernt KM. MLL-
rearranged leukemias—An update 
on science and clinical approaches. 
Frontiers in Pediatrics. 2017;5:1-21
[30] Liedtke M, Cleary ML. Therapeutic 
targeting of MLL. Blood. 2009;113(24): 
6061-6068
[31] Marcucci G, Mrózek K, Radmacher 
MD, Garzon R, Bloomfield CD. The 
prognostic and functional role of 
microRNAs in acute myeloid leukemia. 
Blood. 2011;117(4):1121-1129
[32] Noren Hooten N, Abdelmohsen K, 
Gorospe M, Ejiogu N, Zonderman AB, 
Evans MK. microRNA expression 
patterns reveal differential expression 
of target genes with age. PLoS One. 
2010;5(5):e10724
77
Proteoforms in Acute Leukemia: Evaluation of Age- and Disease-Specific Proteoform Patterns
DOI: http://dx.doi.org/10.5772/intechopen.90329
[33] Daschkey S, Röttgers S, 
Giri A, Bradtke J, Teigler-Schlegel A, 
Meister G, et al. MicroRNAs distinguish 
cytogenetic subgroups in pediatric AML 
and contribute to complex regulatory 
networks in AML-relevant pathways. 
PLoS One. 2013;8(2):e56334
[34] Lawrence M, Daujat S, 
Schneider R. Lateral thinking: How 
histone modifications regulate gene 
expression. Trends in Genetics. 
2016;32(1):42-56
[35] Ryan JM, Cristofalo VJ. Histone 
acetylation during aging of human 
cells in culture. Biochemical and 
Biophysical Research Communications. 
1972;48(4):735-742
[36] Feser J, Tyler J. Chromatin structure 
as a mediator of aging. FEBS Letters. 
2011;585(13):2041-2048
[37] Bhatla T, Wang J, Morrison DJ, 
Raetz EA, Burke MJ, Brown P, et al. 
Epigenetic reprogramming reverses 
the relapse-specific gene expression 
signature and restores chemosensitivity 
in childhood B-lymphoblastic leukemia. 
Blood. 2012;119(22):5201-5210
[38] Bacher U, Schnittger S, Macijewski K, 
Grossmann V, Kohlmann A, Alpermann T, 
et al. Multilineage dysplasia does not 
influence prognosis in CEBPA-mutated 
AML, supporting the WHO proposal to 
classify these patients as a unique entity. 
Blood. 2012;119(20):4719-4722
[39] Friedman AD. C/EBPα in 
normal and malignant myelopoiesis. 
International Journal of Hematology. 
2015;101(4):330-341
[40] Aebersold R, Mann M. Mass 
spectrometry-based proteomics. Nature. 
2003;422(6928):198-207
[41] Hillenkamp F, Karas M, 
Beavis RC, Chait BT. Matrix-assisted 
laser desorption/ionization mass 
spectrometry of biopolymers. Analytical 
Chemistry. 1991;63(24):1203A
[42] Cai W, Tucholski TM, 
Gregorich ZR, Ge Y. Top-down 
proteomics: Technology advancements 
and applications to heart diseases. 
Expert Review of Proteomics. 
2016;13(8):717-730
[43] Lisitsa A, Moshkovskii S, 
Chernobrovkin A, Ponomarenko E, 
Archakov A. Profiling proteoforms: 
Promising follow-up of proteomics for 
biomarker discovery. Expert Review of 
Proteomics. 2014;11(1):121-129
[44] Schaffer LV, Millikin RJ, Miller RM, 
Anderson LC, Fellers RT, Ge Y, et al. 
Identification and quantification of 
proteoforms by mass spectrometry. 
Proteomics. 2019;19(10):e1800361
[45] Kornblau SM, Coombes KR. Use 
of reverse phase protein microarrays to 
study protein expression in leukemia: 
Technical and methodological lessons 
learned. Methods in Molecular Biology. 
2011;785:141
[46] Cui J, Wang J, He K, Jin B, 
Wang H, Li W, et al. Two-dimensional 
electrophoresis protein profiling as 
an analytical tool for human acute 
leukemia classification. Electrophoresis. 
2005;26(1):268-279
[47] Cui J, Wang J, He K, Jin B, Wang H, 
Li W, et al. Proteomic analysis of human 
acute leukemia cells: Insight into their 
classification. Clinical Cancer Research. 
2004;10(20):6887-6896
[48] Xu Y, Zhuo J, Duan Y, Shi B, Chen X, 
Zhang X, et al. Construction of protein 
profile classification model and screening 
of proteomic signature of acute leukemia. 
International Journal of Clinical and 
Experimental Pathology. 2014;7(9):5569
[49] Kornblau SM, Tibes R, Qiu YH, 
Chen W, Kantarjian HM, Andreeff M, 
Proteoforms - Concept and Applications in Medical Sciences
76
[18] Bolouri H, Farrar JE, Triche TJ, 
Ries RE, Lim EL, Alonzo TA, et al. The 
molecular landscape of pediatric acute 
myeloid leukemia reveals recurrent 
structural alterations and age-specific 
mutational interactions. Nature 
Medicine. 2018;24(1):103-112
[19] Ley TJ, Miller C, Ding L, 
Raphael BJ, Mungall AJ, 
Robertson AG, et al. Genomic and 
epigenomic landscapes of adult de 
novo acute myeloid leukemia. The 
New England Journal of Medicine. 
2013;368(22):2059-2074
[20] Papaemmanuil E, Gerstung M, 
Bullinger L, Gaidzik VI, Paschka P, 
Roberts ND, et al. Genomic 
classification and prognosis in 
acute myeloid leukemia. The New 
England Journal of Medicine. 
2016;374(23):2209-2221
[21] Gamis AS, Alonzo TA, 
Perentesis JP, Meshinchi S. Children's 
oncology Group's 2013 blueprint 
for research: Acute myeloid 
leukemia. Pediatric Blood & Cancer. 
2013;60(6):964-971
[22] Gygi SP, Rochon Y, Franza BR, 
Aebersold R. Correlation between 
protein and mRNA abundance in 
yeast. Molecular and Cellular Biology. 
1999;19(3):1720-1730
[23] Mun D, Bhin J, Kim J, Kim S, 
Kim HK, Kim DH, et al. Proteogenomic 
characterization of human early-
onset gastric cancer. Cancer Cell. 
2019;35(1):124.e10
[24] Zhang B, Wang J, Wang X, 
Zhu J, Liu Q , Shi Z, et al. Proteogenomic 
characterization of human 
colon and rectal cancer. Nature. 
2014;513(7518):382-387
[25] Perez-Andreu V, Roberts KG, Xu H, 
Smith C, Zhang H, Yang W, et al. A 
genome-wide association study of 
susceptibility to acute lymphoblastic 
leukemia in adolescents and young 
adults. Blood. 2015;125(4):680-686
[26] Zuurbier L, Petricoin EF, 
Vuerhard MJ, Calvert V, Kooi C, 
Buijs-Gladdines JGCAM, et al. The 
significance of PTEN and AKT 
aberrations in pediatric T-cell 
acute lymphoblastic leukemia. 
Haematologica. 2012;97(9):1405-1413
[27] Trinquand A, Tanguy-Schmidt A, 
Ben Abdelali R, Lambert J, Beldjord K, 
Lengliné E, et al. Toward a NOTCH1/
FBXW7/RAS/PTEN–based 
oncogenetic risk classification of 
adult T-cell acute lymphoblastic 
leukemia: A group for research in 
adult acute lymphoblastic leukemia 
study. Journal of Clinical Oncology. 
2013;31(34):4333-4342
[28] Bolouri H, Farrar JE, Triche T, 
Capone S, Ramsingh G, Ries RE, et al. 
The molecular landscape of pediatric 
acute myeloid leukemia reveals 
recurrent structural alterations and age-
specific mutational interactions. Nature 
Medicine. 2019;24(1):103-112
[29] Winters AC, Bernt KM. MLL-
rearranged leukemias—An update 
on science and clinical approaches. 
Frontiers in Pediatrics. 2017;5:1-21
[30] Liedtke M, Cleary ML. Therapeutic 
targeting of MLL. Blood. 2009;113(24): 
6061-6068
[31] Marcucci G, Mrózek K, Radmacher 
MD, Garzon R, Bloomfield CD. The 
prognostic and functional role of 
microRNAs in acute myeloid leukemia. 
Blood. 2011;117(4):1121-1129
[32] Noren Hooten N, Abdelmohsen K, 
Gorospe M, Ejiogu N, Zonderman AB, 
Evans MK. microRNA expression 
patterns reveal differential expression 
of target genes with age. PLoS One. 
2010;5(5):e10724
77
Proteoforms in Acute Leukemia: Evaluation of Age- and Disease-Specific Proteoform Patterns
DOI: http://dx.doi.org/10.5772/intechopen.90329
[33] Daschkey S, Röttgers S, 
Giri A, Bradtke J, Teigler-Schlegel A, 
Meister G, et al. MicroRNAs distinguish 
cytogenetic subgroups in pediatric AML 
and contribute to complex regulatory 
networks in AML-relevant pathways. 
PLoS One. 2013;8(2):e56334
[34] Lawrence M, Daujat S, 
Schneider R. Lateral thinking: How 
histone modifications regulate gene 
expression. Trends in Genetics. 
2016;32(1):42-56
[35] Ryan JM, Cristofalo VJ. Histone 
acetylation during aging of human 
cells in culture. Biochemical and 
Biophysical Research Communications. 
1972;48(4):735-742
[36] Feser J, Tyler J. Chromatin structure 
as a mediator of aging. FEBS Letters. 
2011;585(13):2041-2048
[37] Bhatla T, Wang J, Morrison DJ, 
Raetz EA, Burke MJ, Brown P, et al. 
Epigenetic reprogramming reverses 
the relapse-specific gene expression 
signature and restores chemosensitivity 
in childhood B-lymphoblastic leukemia. 
Blood. 2012;119(22):5201-5210
[38] Bacher U, Schnittger S, Macijewski K, 
Grossmann V, Kohlmann A, Alpermann T, 
et al. Multilineage dysplasia does not 
influence prognosis in CEBPA-mutated 
AML, supporting the WHO proposal to 
classify these patients as a unique entity. 
Blood. 2012;119(20):4719-4722
[39] Friedman AD. C/EBPα in 
normal and malignant myelopoiesis. 
International Journal of Hematology. 
2015;101(4):330-341
[40] Aebersold R, Mann M. Mass 
spectrometry-based proteomics. Nature. 
2003;422(6928):198-207
[41] Hillenkamp F, Karas M, 
Beavis RC, Chait BT. Matrix-assisted 
laser desorption/ionization mass 
spectrometry of biopolymers. Analytical 
Chemistry. 1991;63(24):1203A
[42] Cai W, Tucholski TM, 
Gregorich ZR, Ge Y. Top-down 
proteomics: Technology advancements 
and applications to heart diseases. 
Expert Review of Proteomics. 
2016;13(8):717-730
[43] Lisitsa A, Moshkovskii S, 
Chernobrovkin A, Ponomarenko E, 
Archakov A. Profiling proteoforms: 
Promising follow-up of proteomics for 
biomarker discovery. Expert Review of 
Proteomics. 2014;11(1):121-129
[44] Schaffer LV, Millikin RJ, Miller RM, 
Anderson LC, Fellers RT, Ge Y, et al. 
Identification and quantification of 
proteoforms by mass spectrometry. 
Proteomics. 2019;19(10):e1800361
[45] Kornblau SM, Coombes KR. Use 
of reverse phase protein microarrays to 
study protein expression in leukemia: 
Technical and methodological lessons 
learned. Methods in Molecular Biology. 
2011;785:141
[46] Cui J, Wang J, He K, Jin B, 
Wang H, Li W, et al. Two-dimensional 
electrophoresis protein profiling as 
an analytical tool for human acute 
leukemia classification. Electrophoresis. 
2005;26(1):268-279
[47] Cui J, Wang J, He K, Jin B, Wang H, 
Li W, et al. Proteomic analysis of human 
acute leukemia cells: Insight into their 
classification. Clinical Cancer Research. 
2004;10(20):6887-6896
[48] Xu Y, Zhuo J, Duan Y, Shi B, Chen X, 
Zhang X, et al. Construction of protein 
profile classification model and screening 
of proteomic signature of acute leukemia. 
International Journal of Clinical and 
Experimental Pathology. 2014;7(9):5569
[49] Kornblau SM, Tibes R, Qiu YH, 
Chen W, Kantarjian HM, Andreeff M, 
Proteoforms - Concept and Applications in Medical Sciences
78
et al. Functional proteomic profiling of 
AML predicts response and survival. 
Blood. 2009;113(1):154-164
[50] Hoff FW, CW H, Qiu Y, 
Ligeralde AA, Yoo SY, Mahmud M, 
et al. Recognition of recurrent protein 
expression patterns in pediatric acute 
myeloid leukemia identified new 
therapeutic targets. Molecular Cancer 
Research. 2018;16(8):1275-1286
[51] Hoff FW, Qiu Y, Kornblau SM, 
De Bont ESJM, Hu CW, Ligeralde A, 
et al. Recurrent patterns of protein 
expression signatures in pediatric acute 
lymphoblastic leukemia: Recognition 
and therapeutic guidance. Molecular 
Cancer Research. 2018;16(8):1263-1274
[52] Hu CW, Qiu Y, Ligeralde A,  
Raybon AY, Yoo SY, Coombes KR,  
et al. A quantitative analysis of 
heterogeneities and hallmarks in 
acute myelogenous leukaemia. 
Nature Biomedical Engineering. 
2019;3(11):889-901
Proteoforms - Concept and Applications in Medical Sciences
78
et al. Functional proteomic profiling of 
AML predicts response and survival. 
Blood. 2009;113(1):154-164
[50] Hoff FW, CW H, Qiu Y, 
Ligeralde AA, Yoo SY, Mahmud M, 
et al. Recognition of recurrent protein 
expression patterns in pediatric acute 
myeloid leukemia identified new 
therapeutic targets. Molecular Cancer 
Research. 2018;16(8):1275-1286
[51] Hoff FW, Qiu Y, Kornblau SM, 
De Bont ESJM, Hu CW, Ligeralde A, 
et al. Recurrent patterns of protein 
expression signatures in pediatric acute 
lymphoblastic leukemia: Recognition 
and therapeutic guidance. Molecular 
Cancer Research. 2018;16(8):1263-1274
[52] Hu CW, Qiu Y, Ligeralde A,  
Raybon AY, Yoo SY, Coombes KR,  
et al. A quantitative analysis of 
heterogeneities and hallmarks in 
acute myelogenous leukaemia. 
Nature Biomedical Engineering. 
2019;3(11):889-901
Proteoforms 
Concept and Applications in Medical Sciences
Edited by Xianquan Zhan
Edited by Xianquan Zhan
A proteoform is the basic unit in a proteome, defined as its amino acid sequence + 
post-translational modifications + spatial conformation + localization + cofactors 
+ binding partners + a function, which is the final functional performer of a gene. 
Studies on proteoforms offer in-depth insights and can lead to the discovery of reliable 
biomarkers and therapeutic targets for effective prediction, diagnosis, prognostic 
assessment, and therapy of disease. This book focuses on the concept, study, and 
applications of proteoforms. Chapters cover such topics as methodologies for 
identifying and preparing proteoforms, proteoform pattern alteration in pituitary 
adenomas, and proteoforms in leukemia.
Published in London, UK 
©  2020 IntechOpen 







962 8 2 0
